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INTRODUCTION 
 
 The siddha system of Medicine is one of the oldest ancient Medicine system 
in the world.  The word siddha comes form  the word  “Siddh “  “ Siddh” means 
heavenly bliss. Siddhars are people who achieved siddhi. They were philosophers, 
healers and men with supernatural powers. 
 While they were apparently  the miracle men, the medical science they 
practiced is Siddha medicine 
 The Siddha system of medicine stress on positive health and gives physical, 
mental, moral, social and spiritual welfare for an individual human. 
  ‘mz;lj;jpy; cs;sNj gpz;lk; 
   gpz;lj;jpy;  cs;sNj mz;lk;”  
      - rl;lKdp epfz;L 
 Based on this above words, Siddhars maintainted their physical and mental 
health and they got spiritual powers for giving good heath of an individuals, free 
from diseases. 
  ‘capiu tsh;f;Fk; cghak; mwpe;Nj 
   clk;ig tsh;j;Njd; ey;caph; tsh;j;NjNd” 
        - jpUke;jpuk; 
 The basic five elements of the universe namely Earth, water, Fire, Air, and 
space, it corresponds to the five senses of our human body and they were  
fundamentals of all the carnal things in the universe  including Man. The Man is a 
miniature of the entire universe and every second changes in the universe affects 
man and vice-versa. 
 For the importance of maintaining good health in the children.  The 
Siddhars were separately mentioned many diseases and treatment, the paediatirc 
medicine is called as Balavagadam (or) Kuzhanthai Maruthuvam. Shortly 
Kuzhanthi Maruthuvam has got more importance than other branches of medicine 
in our siddha system and also the treatment aspect of paediatric medicine is very 
special inimiatable. 
 
 
 In Paediatirc age group Infectious diseases  and  nutritional  deficiencies are 
very  common and affect their growth and developemt. Of all the paediatirc 
infectious diseases. LASUNATHABITHAM (tonsillitis) is one of the most 
common diseases. 
 Treatment of the infections diseases in children is very important because it 
spoils the children growth both physically and mentally. 
 So, the Management of LASUNATHABITHAM is very special, tonsils 
are the warriors of lungs. Infection of Tonsils leads to affect the lungs and immune 
system of children. 
  Keeping this in mind for bringing out an effective and special treatment to 
LASUNATHABITHAM from our special Siddha medicine system the author has 
under taken the dissertation work with drug LASUNATHABITHA KUDINEER. 
 The author tentatively does this work to the honour of siddha system of 
Medicine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM AND OBJECTIVE. 
AIM:- 
  The principle aim of the present study is to evaluate the efficacy of the trail 
drug LASUNATHABITHA KUDINEER in the treatment of 
LASUNATHABITHAM. 
OBJECTIVES:- 
1.  The main objective of the present study is to create awareness about the 
 siddha system and to highlight the efficacy of Siddha drug among  the 
 public people. 
2. To study the Casue, clinical Features, diagnosis and investigation of 
 lasunathabitham through various siddha literatures. 
3.  To figure out the biochemical and pharmacological activites of the drug. 
4.  To make the correspondent study of the siddha and modern aspect of the 
 disease. 
5.  To study the pre- clinical analytical standardization and safety study in the 
 experimental formulation of lasunathabitha kudineer. 
6.  To flash the solitary diagnostic procedure mentioned in Siddha literature of 
 the  disease lasunathabitham. 
7.  To oversight the clinical trial  and  to final out the efficacy of 
 Lasunathabitha  kudineer  for the cure of the disease Lasunathabitham. 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
SIDDHA ASPECT 
,yRz jhgpjk; 
NtW ngah;fs; 
ngah; fhuzk; : 
 ‘yRz jhgpjk;” vDk; nrhy; gy tpsf;fSld; gy;NtW Ehy;fs; 
vLj;jpak;GfpwJ. 
 mitfSs;> TV rhk;grptk; gps;is kUj;Jt nrhy; mfuhjpapy;> 
fPo;fhZkhW ‘,yRzjhgpjk;” vDk; nrhy; tpsf;fg;gLfpwJ. (1-6) 
                          Pg:-223 
1. mz;zhf; fow;rp 
 Nky;thapd; fPo;g;Gwj;jpw; fhZk; jhgpjk;. 
2. cz;zhf;fow;rp 
 mz;zj;jpypUf;Fk; rijf;Nfw;gLk; Ntf;fhL. 
3. cz;zhf;Fj;jy; 
 cs;ehf;F ePz;L tsh;e;J njhz;iliaf; Fj;jp epw;wy;. 
4. cz;zhf;F Nuhfk; 
 cz;zhf;fpy; rij tsh;e;J tPf;fj;ij cz;lhf;fp ,UkiyAk;> 
mWFjiyA Kz;lhf;Fk; Neha;. 
5. mz;zhf;Fj; J}W jhgpjk; [Fzg;ghlk; jhJ rPt tFg;G] 
      -kU.,uh.jpahfuh[d;> vy;.I.vk;. Pg.No:-645 
6. njhz;ilapy; tsUk; rij - Neha;fSf;F rpj;j ghpfhuk;  
                      -kU.k.rz;KfNtY.vr;.gp.[.vk;.(99) 
7.njhz;il fpue;jp tPf;fk; - itj;jpak; (monthly edition from srilanka) 
8. njhz;il J}W 
9. njhz;ilf; fl;b 
10. njhz;il NehT 
             Mjhuk; - lexicon vol 4 
          jkpo; mfuhjp 2092>2093. 
 
 
 
,ay;: 
 njhz;ilapYk;> khh;gpYk; NfhioAz;lhfp mjid 
ntspNaw;Wtjw;Fk;> fgk;> gpj;jk; ,it jd;dpiy gpwo;e;J njhz;il> 
cz;zhf;F Mfpa ,lq;fspy; jhgpjj;ij (Gz;iz) cz;lhf;Fk;. ,jid 
‘cz;zhf;F jhgpjk;” (m) ‘,yRzjhgpjk;” vd;gh;. 
      - gps;isgpzp kUj;Jtk; -   
          ghfk;-1  
               gf;fk;-111 
          ,yRzk;+jhgpjk; 
 ,yRzk; 
 ,yRzk; vd;gJ njhz;ilapd; mf;fk; gf;fq;fspy; 
nkd;dz;iyj;jpd; Kd; gpd; epiyfSf;F ,ilapy; gf;fj;Jf; 
nfhd;wha; ,Uf;fpw Ntg;gq;nfhl;il tbtkhd ,uz;L 
cWg;GfshFk;. 
 jhgpjk; 
 jhgpjk; vd;gJ clk;gpd; vg;gFjpapyhtJ #L cz;lhfp rpte;J 
typAld; cz;lhFk; tPf;fk;. NkYk; mt; cWg;Gfspy; mow;rp Vw;gLk;. 
vdNt> yRz jhgpjj;jpy; yRzk; jhgpjkile;J rpte;j epwkiljy;> 
Ruk; njhz;ilapy; typAld; $ba tPf;fk; Mfpa FwpFzq;fs; 
Vw;gLk;. 
           - clw;$W 
Neha; tUk; top:- 
 fhuzk;:- 
 ‘njhz;iljdpy; NehaZFk; fhuze;jhd;  
  #l;rkjha; nrhy;YfpNwd; Rfkha; NfS 
 mz;lh; Kjy; Njth;fis mgkhdpj;Jk; 
  mbahiu kpf gopj;J jhl;rzpj;Jk; 
 nfhz;ltiu Ngzhky; jha; je;ijf;Fk; 
  nfhLik kpf nra;J Nfhgpj;Nj jhd;  
 gz;baJ epiwa cz;L grpj;Njhh;f;fPah  
  ghjfw;Fk; njhz;il NehaDFJ nkd;Nw”. 
 
 
 
nghUs;:- 
  njhz;ilapy; vOk; Nehapd; fhuzj;ij tpsf;ff; Nfsha;> 
kdpjh;fs; Kjy; Njth;fis mgkhdpj;jjhYk;> rpt gf;jh;fis gopj;Jk;> 
mh;g;gkhf NgrpajhYk;> jd;id mz;bath;fis cjhrPdk; 
gLj;jpajhYk;> jha; je;ijah;fis Nfhgpj;J nfhLikg; gLj;jpajhYk;> 
jhd; ed;whf Grpj;J> grpj;J fplg;NghUf;F juhjjhYk; njhz;il Neha; 
Vw;gLfpwJ. 
  ‘NehaJ jd; Kd; nrd;k rhgj;jhYk; 
   nehe;J kdnjhpe;J jpid ittjhYk; 
  jhafkhk; je;ij jha; FLk;gj; Njhh;fs; 
   jid mjpfk; tUe;jplNt nra;j Njh\k; 
  khakjha; te;J gw;wp tUj;jk; nra;Ak; 
   tifaJ jhd; fhaj;jhNy Vkj;jhYk; 
  fhakjpy; NtnyOk;gp ePh;jhNdw;W  
   fhl;Lklh njhz;il NehapJ jhd; fhNz”. 
nghUs;:- 
  NkYk; Kd; nrd;kj;jpy; nra;j ghtr; nrayhy; tpise;j 
rhgj;jhYk;> jha; je;ij> FLk;gj;jhh; kdk; nehe;J VrpajhYk;> 
fhaj;jhYk;> Vkj;jhYk; clypy; Neh;e;j ghjpg;ghy;> ePh; Nfhh;j;J 
njhz;ilapy; Neha; vOk;. 
             - Foe;ij fz;-nrtp-njhz;il 
          (kUj;Jtk;) gf;fk;-45>46 
        Dr.s.rpjk;gujhZg; gps;is. 
  ‘nrhy;ypa nrd;d $w;why; Jlh; gotpidahYk; te;J 
   ey;ytDWg;gpd; rhh;e;J kUtpa Njh\j;jhYk; 
   my;yfrpurpy; ePuhy; md;idapy; ghypdhYk; 
   fy;yf euk;gpy; jhtp fgkJ te;J rhUk;. 
 
 
 
 
 
 
 
nghUs;:- 
 fh;k tpidahYk;> cWg;ig rhh;e;j Njh\j;jhYk; jiyf;F jz;zPh; 
Cw;wp rhptu Jtl;lhJ ,Uj;jyhYk;> md;idapd; jha; ghypd; Nfl;lhYk;> 
Foe;ijapd; clypd; euk;gpy; Njh\k; jhtp fgk; Vw;gLk;. 
 
  ‘rhUNk rpurpy; epd;W jifj;jpLk; FtL njhz;il 
   thUNk tpyhT neQ;R kUtpa cWg;G jd;dpy; 
  ePUNk ciwe;J fgKk; epd;wJ twl;rpahfp  
   $UNk nfhL ePuhfp Foe;ijNky; mUnkd;Nw. 
nghUs;:-  
  rpurpypUe;J FtL> njhz;il> tpyh> neQ;R Kjypa 
cWg;Gfspy; ciwe;j fgk;> twl;rpahfp  Foe;ijfspy; ePuhf MFk;. 
       -Foe;ij Neha;fs; ghfk;V 
            gf;fk;1>2 
         (rpjk;gujhDg; gps;is) 
 
Neha; tUk; top:- 
   kpF Fsph;r;rp> kpFe;j ntg;gk; cs;s nghUl;fis kpFjpahf 
 cz;zy;. 
 ,dpg;G> Gspg;G RitAs;s nghUl;fis mjpfk; cz;ZtjhYk;. 
 Fsph;e;j ePh; ;>  gioa NrhW Mfpatw;iw cl;nfhs;tjhYk;. 
 fpoq;F tiffis mjpfk; cz;gjhYk;. 
 JhR> Giffspy; <LgLtjhYk; ,e;Neha; cz;lhfpwJ.. 
                 -A+fp itj;jpa rpe;jhkzp 800 
Nehapd; Kw;FwpFzq;fs;:- 
 njhz;il cyh;jy; 
 ,Ukp ,Ukp njhz;ilia rptf;f nra;jy;. 
 njhz;ilapy; VNjh G+rpaJ NghYk;> njhz;il ,Wf;fpaJ Nghd;Wk; 
  czh;r;rpAz;lhjy;.  
        ‘Neha;ehly; ghfk;-II 
          gf;fk;-70 
 
 
Nehapd; FwpFzq;fs;:- 
 njhz;il Gz;gl;ljdhy; typ Vw;gly;. 
 njhz;il rptj;jy; 
 FuNyhir Fiwjy; 
 Ruk; fha;jy; 
 ,Uky; 
 %r;R jLkhwy; 
 fhJ typ 
 %f;fpypUe;J ePh; tbjy; 
 %f;filg;G 
 jiyfdj;jy; 
 cly; td;ikf; Fiwjy; 
 czT nghUl;fs; tpOq;f Kbahik. 
rpq;q Nrw;g Fzk:; 
 ‘cs;ehf;F njhz;il gw;wp Cdkha; tPq;fp nehe;J 
  nts;sNt fgk;te;Njwp ntwpruk; miyapNw 
  cs;sePh; ghy; nfhs;shJ cWg;ngy;yhk; nte;JthLk; 
  Ks;sNt rpq;q Nrw;gk; kuznkd;W vz;zplhNa...” 
nghUs;:- 
   rpq;q Nrw;gdj;jpd; fhuzkhf cs;ehf;F> njhz;il ,tw;wpy; 
tPf;fk; vOe;J> nehk;gyk; jUk;. fgk; vOe;J RuKk; mdyha; fhAk;. 
Foe;ij ghy; FbahJ. cWg;ngy;yhk; nte;J thLk; rpq;q Nrw;gdk; NfL 
tpistpf;fhJ vd;gij mwpaTk;. 
tiffs;:- 
  ,yRz jhgpjj;jpd; tiffs; gy;NtW Ehw;fspy; gy tpjkhf 
Fwpf;fg;gl;Ls;sd. mitfSs; ‘4448 tpahjpfs;” vDk; Ehypy; 
lhf;lh;.r.muq;fuhrd; Mrphpahpd; $w;Wg;gb> 
 ‘tuk; gilj;J ,yq;Fq; fPh;j;jp 
  kz;Z NfOk; tz;zj; 
  juk; gilj;J ,yq;Fk; vd;g 
  cz;ikahy; kdpjh; jq;fs; 
 
 
  rpuq;fNeha; jhNd nrg;gpr;  
  NrUk; Nehapd; Ngh; vypsk; 
 gue;j ew;fy;tpNahL 
  gz;gpdh Yiuf;f Yw;Nwd;”. 
nghUs;:- 
 Nkd;ik nghUe;jp tpsq;Fk; VO cyfj;jpdUk; cz;ikahd 
kdpjh;fSf;Fk; rpuk; Kjy; vy;yh mq;fq;fspYk; tUk; Nehapd; ngaiu 
vy;yhk; vd; mwptpdhy; gz;NghL nrhy;Yfpd;Nwd;. 
1. ............ 
 ‘ehtJ jd;dpy; ehw;gj;njhd;gJ 
   NkT> rpW ehtpy; tpsq;fpLkhW 
   njhz;il mjdpy; #o;e;jpLk; gpzpfs; 
  fz;lk; tiuf;Fk; foW Ehw;W ,UgJ 
                -4488 gf;fk; -24 
nghUs;:- 
 cs; ehf;F Neha;fs; 6 tiffs; 
  njhz;il fOj;J Mfpa ,lq;fspy; tUk; Neha;fs; 120 vd   
  Mrphpah; $wpapUf;fpwhh;. 
2. ‘Njiuah; thfl Ehypy; Fwpg;gpl;lthW” 
     ........ 
 ‘cjpur; raKk; cah;e;j ePh;f; fLg;Gk; 
  fz;le; jd;dph; ftpe;j mlf;fKk;...... 
       gf;fk; 223. 
nghUs;:-  
 clypy; Iak; kpFe;J> ePh; fLg;Gk;> njhz;ilapy; fgk; milj;Jf; 
nfhs;Sk;. 
3. ‘MFk; vz;ehd;F je;jkjdpy; Neha; ehw;gj;ije;jhk; 
    Njhifia rpFit jd;dpy; NuhfKQ; nrhypYk; fhiy 
    ehfkh Kdp ciuj;jhh; Kg;gj;J ehyh vd 
    ghfkh mwp cz;zhf;fpy; gw;W Neha; ,UgjhNk”. 
                 -ehfKdp jiyNeha; 
          gf;fk; (2) 
 
 
nghUs;:- 
 ehfKdp jiyNeha; Ehypd; $w;Wg;gb> cs;zhf;F Neha;fs; 20 
tifg;gLk;. 
4. rpj;jh; mWit kUj;Jt Ehypy; $wpagb cs;ehf;F-20 tifg;gLk;. 
                  - Dr. c.s. cj;jkuhad;  
           gf;fk;-98 
5. ruNge;jpu itj;jpa rpuNuhfk; vDk; Ehypd; $w;Wg;gb. 
              -njhz;il Neha;fs;-15 tif cz;L. 
6. [Ptul;rhkph;jk; vDk; ciwapd; $w;Wgb njhz;ilNeha;fs;-18tiffs;. 
                       -Rg;gpukzpa gz;bjh; 
                gf;fk; 253. 
epzf;Fwy; fk;ky:; 
  ‘Fuy;tis epzq;Nfhio nfhz;L jlty; Nghy; 
        tpuTtOg; igf;Fz;ePh; Ntl;f;if - jUNky; 
   tzg;Ngr; rwptpd;ik tha;nghWj;Jg; Ngry; ‘ 
 
nghUs;:- 
  ‘epzf;Fuy;fk;ky; Nehapy;> rpWtajpdh;f;F Fsph;fhw;W> Fsph;e;j ePh;> 
czT ,tw;why; njhz;il rpte;J Iaq;$b njhz;ilapy; rij tsUk;. 
 ,r;rij ehSf;F ehs; tsh;e;J> Fuy;tisia ,Wf;fp> 
Fuy;fk;ky; Nehia cz;lhf;Fk;. 
 ,j;Jld; Ruk;> njhz;ilNeha;> tha;ehw;wk>; %f;fpy; ePh; tbjy;> 
fhjpy; rPo; tbjy;> ,Uky; Njhd;Wjy;> %r;Rj; jilgly; Kjypa 
FwpFzq;fisAk; fhl;Lk; vd;W $wpAs;sdh;. 
 
        -rpj;j kUj;Jtk; (nghJ) 
  
 
 
  
  
 
 
Kf;Fw;w NtWghL:- 
 fg ];jhdkhfpa njhz;ilapy; moy; Fw;wkhdJ jd;dstpy; 
kpFjpg;gl;L> tspf;Fw;wj;iijj; Jizf; nfhz;L> tPf;fk;> ,yRzk; 
rptj;jy;> typ Kjypa FwpFzq;fis cz;lhff; $ba jd;ik cilajhf 
mikfpwJ. 
  ‘kpfpDk; FiwapDk; Neha; nra;Ak; E}Nyhh; 
   tspKjyh ntz;zpa %d;W” 
        -jpUf;Fws; 
vDk; Nkw;Nfhspd; gb ,e;Neha; epiyapy; Kf;Fw;wq;fSk; jd;dpiyapy; 
jphpe;J epw;fpwJ. jd;dpiyapy; rPj tPhpak; mjpfKila czTg; nghUl;fs; 
(Fsph;e;j jz;zPh;> rUFfs; Cwpa gioa jz;zPh;) Nghd;witfis 
cl;nfhs;Sk; NghJ ,aw;ifahf mike;jpUf;fpd;w moy; Fw;wkhdJ rPj 
tPhpaj;jhy; J}z;lg;gl;L njhz;ilapy; Njq;fp epd;W ,yRzq;fs; jbg;Gk;> 
jsh;r;rpAk; cz;lhfpwJ. 
 ,it ,uz;Lk; NtWgLtjd; fhuzj;jpdhy;> ,aw;if top epd;w 
tspf;Fw;wk; Jizf; fhuzkhfp Ntw;Wepiy tsh;r;rpaile;J 
,yRzj;ijf; jhgpjg;gLj;Jfpd;wd.   
 
   rPj tPhpaKila czTg;nghUl;fs; Fsph;e;j ePh;> rUFfs; Cwpa gioa  
                        ePh; mUe;Jjy; 
 
fg ];jhdj;jpy; (njhz;il) 
 
rPj tPhpak; 
 
gpj;jk; jd;dstpy; mjpfg;gLk; 
 
,yRzk; jbg;G> jsh;r;rp cz;lhFk; 
 
thj Fw;wk; Ntw;Wepiy tsh;r;rpailfpwJ 
 
 
 
tPf;fk;> ,yRzk; rptj;jy;> typ ,Uf;Fk; 
 
,yRzk; jhgpjkilfpwJ 
Neha;fzpg;G:- 
rpj;j kUj;Jt Neha;fzpg;G:- 
 gpzpawp Kiwik 
 caph; jhJf;fs; 
 cly; jhJf;fs; 
 gUtq;fs;  
 Itif epyq;fs; 
 cly; td;ik 
 vz; tifj;Njh;Tfs; 
 ePh;Fwp 
 nea;Fwp 
 ehb 
Nkw;Fwpa fhuzpfspd; khWghLfis xd;Wld; xd;W xg;gpl;Lf; 
fzpf;fg;gLfpwJ. 
gpzpawp Kiwik:- 
 1. nghwpahy; mwpjy; 
 2. Gydhy; mwpjy; 
 3. tpdhjy; 
,yRzjhgpjj;jpy; Nehahspf;F fhZk; FwpFzq;fs;. 
1. nghwpahy; mwpjy; 
 %f;F - %f;filg;G/%f;FePh;gha;jy; 
 eh  - Nfhio Eiuj;jy; 
 fz; - ,ay;G 
 fhJ - fhJ typ 
 Njhy; - ,ay;G 
 
 
 
 
 
2. Gydhy; mwpjy; 
 CW - ntg;gk; 
 Xir - ,ay;G 
 xsp - ,ay;G 
 Rit - ,dpg;G Rit njhpjy; 
 ehw;wk; - %f;fpy; rsp rt;T rpte;Jf;fhzy;> %f;filg;G. 
3. tpdhjy;:- (Nfl;lwpjy;) 
 kUj;Jtd; jd; nghwp> Gydhy; Nehahspapd; epiy gw;wp 
czh;e;jij NehahspaplNkh (m) mtd; ngw;Nwhh; Rw;wj;jhiuf; 
nfhz;Nl mtdJ ngah;> taJ> jpiz> FLk;g tuyhW> czT 
gof;ftof;fk;> Ke;ija Nehapd; tuyhW> Nghd;wtw;iw mwpjy; 
MFk;. 
 ,itad;wp> msit %yKk; gpzpia mwpa KbAk;. 
msit-10 tifg;gLk;. 
vdpDk;> 
  fhz;ly; 
  fUjy; 
  ciu vd;Dk; ,k;%d;W msitapy; 10 msitfSk;  
  mlq;Fk;. 
fhz;ly;:- 
   Nehahspapd; njhz;il> cs;ehf;if ghh;j;jy;. 
fUjy;:- 
 Nehahsp $Wk; FwpFzq;fshd czT> ePh; tpOq;f rpukk;> Ruk;> 
jiytyp> ,Uky;> fhJtyp Kjypad. 
ciu:- 
   Nehia rhpahd Kiwapy; fzpj;J ciuj;jy;. 
 
 
 
 
 
 
 
caph;jhJf;fs; (Kf;Fw;wk;) :- 
1. thjk; 
yRzjhgpjj;jpy; fhzg;gLk; thjj;jpd; epiy:- 
 1. gpuhzd;  : ghjpg;G (,Uky;> Nfhio ntsptuy;) 
 2. mghdd;  : ,ay;G 
 3. tpahdd;  : ghjpg;G (czT tpOq;Fk; NghJ   
      njhz;ilapy;  typ) 
 4. cjhdd;  : ghjpg;G (Ngr;nrhyp Fd;wy;> ,Uky;) 
 5. rkhdd;  : ghjpg;G (kw;w thAf;fis fl;Lg;gLj;Jtjpy; 
               rpukk;) 
 6. ehfd;  : ,ay;G 
 7. $h;kd;  : ,ay;G 
 8. fpUfud;  : ghjpg;G (,Uky;> %f;fpy; ePh; tbjy;) 
 9. Njtjj;jpd; : ghjpg;G (Nrhk;giy cz;lhf;Fjy;) 
   10. jdQ;nrad; : - 
2. gpj;jk; 
,yRzjhgpjj;jpy; gpj;jj;jpd; epiy:- 
 1. mdw;gpj;jk; : ,ay;G 
 2. ,uQ;rfgpj;jk; : ,ay;G 
 3. rhjfg;gpj;jk; : ghjpg;G (cz;Zk; NghJ  njhz;ilapy;  
          typ> cly; Nrhh;T) 
 4. gpuhrfgpj;jk; : ,ay;G 
 5. MNyhrfgpj;jk; : ,ay;G 
3. fgk; 
,yRzjhgpjj;jpy; fgj;jpd; epiy:- 
 1. mtyk;gfk; : ghjpg;G(%r;R tpl rpukk;) 
 2. fpNyjfk;  :  ,ay;G 
 3. Nghjfk;  : ,ay;G 
 4. jw;gfk;  :  ,ay;G 
 5. re;jpfk;  : ,ay;G 
 
 
 
 
cly; jhJf;fs;:- (VO clw;fl;Lfs;) 
,yRzjhgpjj;jpy; clw;fl;Lfspd; epiy:- 
 1. rhuk;  : ghjpg;G (cly; Nrhh;T) 
 2. nre;ePh;  : ghjpg;G (fPopik ePf;fp ghh;f;fpd; ntSg;G  
          fhzy;) 
 3. Cz;  : ghjpg;G ( njhz;ilapy; typ ,yRzk;  
           tPf;fk;) 
 4. nfhOg;G  : ,ay;G 
 5. vd;G  : ,ay;G 
 6. %is  : ,ay;G 
 7. Rf;fpyk; 
   /RNuhzpjk; : ,ay;G 
gUtfhyq;fs;:- 
 ngUk;nghOJ - gd;dpuz;L jpq;fs; ,g;ngUk;nghOij MW gUt 
fhyq;fshfg; gphpf;fg;gl;Ls;sJ. ,g;gUt fhyq;fspd; khw;wj;ijg; 
nghWj;J Neha;fs; Vw;glf;$Lk;. vdNt> gUt fhyq;fspd; Jizahy; 
gzpia mwpathk;. 
 1. fhh;fhyk;  : Mtzp> Gul;lhrp (Aug $ Sep)  
 2. $jph;fhyk; : Ig;grp> fhh;j;jpif (Oct $ Nov) 
 3. Kd;gdpf; fhyk; : khh;fop> ij (Dec $ Jan) 
 4. gpd;gdpf; fhyk; : khrp> gq;Fdp (Feb $ Mar) 
 5. ,sNtdpy; : rpj;jpiu>itfhrp (April $ May) 
 6. KJNtdpy; : Mdp> Mb (June $ July) 
 
 
 
 
 
 
 
 
 
 
Kf;Fw;wq;fSk;> gUtf;fhyq;fSk;> RitfSk;. 
t. 
vz; 
gUtf; fhyq;fs; Fw;wq;fs; Fw;wq;fspd; epiy Rit 
1. fhh;fhyk; thjk; Ntw;Wepiy tsh;r;rp ,dpg;G> Gspg;G> 
cg;G 
  gpj;jk; jd;dpiy tsh;r;rp  
2. $jph;fhyk; thjk; jd;dpiy tsh;r;rp ,dpg;G> ifg;G> 
Jth;g;G 
  gpj;jk; Ntw;Wepiy tsh;r;rp  
3. Kd;gdpf;fhyk; gpj;jk; jd;dpir tsh;r;rp ,dpg;G> Gspg;G> 
cg;G 
4.  gpd;gdpf;fhyk; fgk; jd;dpir tsh;r;rp ,dpg;G> Gspg;G> 
Jth;g;G 
5. ,sNtdpy; 
fhyk; 
fgk; Ntw;Wepiy tsh;r;rp ifg;G> Jth;g;G 
6. KJNtdpy; 
fhyk; 
thjk; jd;dpiy tsh;r;rp ,dpg;G 
 
,yRzjhgpjj;jpy; gUtfhyq;fs;:- 
 ,yRzjhgpjj;jpy; gpj;jNjhlk; ghjpg;gile;J jd;dpiy tsh;r;rp 
mile;J mjd;gpd;dh;> fgkhdJ jd;dpiy tsh;r;rp mile;J> Ntw;W 
epiyapYk; tsh;r;rp mile;J ,yRzjhgpjj;jpd; FwpFzq;fis 
cz;lhFf;fpd;wJ. 
 vdNt> Kd;gdp;fhyk; Kjy; ,sNtdpy; tiuAs;s fhyk; 
,yRzjhgpjk; Njhd;Wtjw;Fhpa fhyq;fshFk;. (Dec to Apr). 
Itif epyq;fs;:- 
1.  FwpQ;rp (kiyAk;> kiy rhh;e;j ,lKk;)-rpNyj;Jk Neha;fSf;F 
 ,Ug;gplk; 
2.  Ky;iy (fhLk;> fhL rhh;e;j ,lKk;)-thj Neha;fSf;F ,Ug;gplk; 
3.  kUjk; (taYk; tay; rhh;e;j ,lKk;)-Kf;Fw;wq;fSk; rkg;gLk; 
4.  nea;jy; (flYk; fly; rhh;e;j ,lKk;)-thjNeha; cz;lhFk; 
5.  ghiy(kzYk;> kzy; rhh;e;j ,lKk;)-Kj;Njhlq;fSf;Fk; ,Ug;gplk;. 
 
 
cly;td;ik:- 
   ,J %d;W tifg;gLk;. 
mit. 
 1. ,aw;if td;ik 
 2. nraw;if td;ik 
 3. fhy td;ik 
1. ,aw;if td;ik 
  ,J Fzq;fs; %d;wpypUe;J ,aw;ifahfNt cz;lhtjhFk;. 
 2. nraw;if td;ik 
  ,J ,aw;ifahf cz;lhd cliy> Kf;Fzq;fSf;F Vw;wthW chpa 
czT> nray;fshYk;> cly; jhJf;fs; ghjpf;fg;glh tz;zk; 
epiyepWj;jf;$ba kUe;JfshYk; Ngzpf; nfhs;tjhy; cz;lhtjhFk;. 
 3. fhy td;ik 
  ,J gUtf;fhyq;fshYk;> tajhYk; cz;lhtjhFk; 
   
vz;tifj; Njh;T:- 
 ‘ehbg;ghprk;  ehepwk; nkhoptpop 
  kyk; %j;jpukpit kUj;JtuhAjk;”. 
nghUs;:- 
 1. ehb 
 2. ];ghprk; 
 3. eh 
 4. epwk; 
 5. nkhop 
 6. tpop 
 7. kyk; 
 8. %j;jpuk; 
 
 
t. 
vz; 
vz;tifj; Njh;Tfspd; ,af;f 
epiy 
,yRz jhkpjj;jpy; cz;lhFk; 
khWgl;l epiy 
1.  ehb:- 
 tsp> moy;> Iak;> fyg;G> 
Kf;Fw;wk; ehbfspd; jd; eil> 
Gweil> ,isj;jy;> fjpj;jy;> 
Fjpj;jy;> Js;sy;> mOe;jy;> 
gLj;jy;> fyj;jy;> Kd;Nehf;F> 
gpd;Nehf;F> gf;f Nehf;F> Roty; 
Mfpa Fwpfis mwpayhk;. 
 gpj;jfgk; 
 fg gpj;jk; 
Nkw;nfhz;l ehb eilfs; 
,yRzjhgpj Nehapy; fhZk;. 
2. ];ghprk;:- 
(njhl;Lg;ghh;j;jy;) 
 #lhapUj;jy; nfhjpj;jpUj;jy;> 
Fsph;e;jpUj;jy;> rpy ,lq;fspy; 
#lhfTk;> Kw;Wk; rpy;ypl;bUj;jy;> 
tpah;j;jpUj;jy;> kwj;jpUj;jy;> 
gpRgpRj;jy;> Njhy; ntbg;G> kaph; 
jbj;jy;> cjph;jy;> rpyph;j;jy;> cly; 
RuRuj;jy;> jbj;jy; gilfSz;- 
lhjy;> Njky; ngwy;> fl;bfs;> 
nrhwp> rpuq;F> Gz;> Giu> Gw;Wfs;> 
tPf;fk; Kjypaitnjd;gLjy;> 
Njfk; ,isj;jy; (m) 
gUj;jpUj;jy; Kjypa 
FwpFzq;fis Muha;tjhk;.  
 ,yRzjhgpjj;jpy; Ruk; 
fhZk; 
 fOj;jpd; mUfpy; cs;s 
epzf;Nfhsq;fspy; tPf;fk; 
,Uf;Fk;. 
3. eh:- 
 thj> gpj;j> Ia> epwk;> gyepwk;> 
khrw;wpUj;jy;> khg;gbe;jpUj;jy;> 
tha; ePh; ngUfy;> twz;bUj;jy;> 
fWj;jpUj;jy;> tha; Gz;zhapUj;-
jy;> gpsT> jbg;G fhzy;> 
 ,yRzjhgpjj;jpy; eh 
ntSj;J fhZk;> Nfhio 
ntz;ik epwj;jpy; ntspg;gLk;> 
Ngr;nrhyp jho;e;J fhzg; gLk;. 
 
 
Xuq;fspy; gs;sk;Nghy; gjpe;jpUj;-
jy;> gw;fspd; epiyik> vapWfspd; 
epiyik> Rit mwpjy;> Ngr;rpd; 
epiyik> ehit ntspNa 
ePl;bdhy; xU Gwkhfr; 
rha;e;jpUj;jy;> tha; Nfhzyha; 
,Uj;jy; Mfpa FwpFzq;fisf; 
ftdpg;gjhFk;. 
4. epwk;:- 
 cly; ghpNrhjidapy; thj> 
gpj;j> Ia epwq;fs;> fyg;G epwk; 
(fWj;jy;> kQ;rspj;jy;> rptj;jy;> 
ePykhjy;> ntspuy;) Kfk; rptj;jy;> 
ntspuy;> tpopAk; gy;Yk; fWj;jy; 
Kjypa Fwpfis mwpjyhk;. 
 ,yRzjhgpjj;jpy; 
njhz;il> ,yRzk; rpte;Jf; 
fhZk;. 
5. nkhop:- 
(Xir) 
 Nehahsp NgRk; nghOJ 
cuj;j xyp> rk xyp> Fuw;fk;kpa 
Ngr;R> jho;e;jxyp> rphpj;jy;> 
gpjw;wy;> Fowy;> rk;ge;jkpy;yhj 
Ngr;R> Nghrhj NghJ fgj;NjhL 
%r;Rtply;> fgj;NjhL $ba 
Ngr;R> %r;Rj; jhq;fp jhq;fp 
tpLtjhfpa EiuaPuypd; xyp 
Kjypa FwpFzq;fis mwpjyhk;. 
 ,yRzjhgpjj;jpy; 
Ngr;nrhyp jho;e;J> Fuy; 
fk;kYld; fhZk;. 
6. tpop:- 
(fz;) 
 fz;zpd; epwk;> fz; 
fyq;fy;> ePh;tbjy;> tPq;fy;> fz; 
ghh;itapd; epiyik> fz; Neha;-
 ,yRzjhgpjj;jpy; tpop 
rpte;J ,Uf;Fk;. 
 
 
 
fs; njhz;Z}w;whiwAk; gw;wp 
Muha;jyhk;. 
7. kyk;:- 
 kyj;jpd; epwk;> jd;ik> 
ehw;wk;> kyj;Jld; rPo;> ,uj;jk; 
,it fye;J Nghjy;> kyk; Nghj- 
yhfpa Fzq;fisAk; ftdpg;g- 
jhFk;. 
 ,yRzjhgpjj;jpy; 
kyf;fl;L ,Uf;Fk;. 
8. rpWePh;:- 
 epwk;> kzk;> fyg;G> Eiu> 
vQ;ry;> Kiw> epiw> rj;J (Rit) 
,itfis Muha;tjhFk;. 
 ,yRzjhgpjj;jpy; rpWePh; 
kQ;rspj;Jk;> rpWj;Jk; 
,wq;Fjy; fhzg;gLk;. 
 
 
 
nea;f;Fwp 
nea;f;Fwpapd; rpwg;G:- 
 ‘If;Fwp nfhLtl thdpo ykh;e;Njhh; 
   iff;Fwp njhpj;j eq;flTisj; Jjpj;Nj 
  nka;f;Fwp epwe;njhzp tpopeh ,Ukyk; 
  iff;Fwp KOtJ}tq; fw;whh; jk;kpDk; 
  ngha;f;Fwp nka;f;Fwp GfY nkth;f;Fk; 
  nea;f;Fwp mjid ,e;epzpyj; Jiug;ghk;”. 
        gf;fk;-298 
        Neha;ehly; ghfk;-1 
 
 
 
 
vz;nza; tpl;L ghh;f;Fk; ePhpd; tpjp:- 
 ‘epwf;Fwpf; Fiuj;j epUkhd ePhpd; 
  rpwf;f ntz;nza; Nahh; rpWJsp eLtpLj; 
  njd;Wwj; jpUe;njhyp Vfhjikj;jjp 
  dpd;wjptiy Nghk; newptpopawpTk;  
  nrd;wJ GfYQ; nra;jpia AzNu.” 
nghUs;:- 
 ePh; epwf;Fwpahy; Nehiaf; fz;L gpbj;jw; nghUl;Lr; 
nrhy;ypapUf;fpd;w tpjp nghUe;jpa rpWePhpy; xU rpwpa Jsp vz;nzia 
eLtpy; ifairtpdhy; vz;nza;j; Jsp rpjwhky; tpl;L nta;apyhdJ 
me;ePhpy; gLk;gb jpwe;J> fhw;whdJ mjpy; tPrp me;j vz;nza;j; Jsp 
Mlhjgb itj;J> mr;rpWePhpy; tplg;gl;bUf;fpd;w vz;nza;j; JspahdJ 
nry;Yfpd;w topapy; fz;zwpitAk;> capuwpitAk; nrYj;jp> mj;Jsp 
njhptpf;Fk; Neha; tpsf;fj;ij eP njhpe;J nfhs;thahf. 
 ‘muntd ePz;bd/Nf thjk;” 
  Mop Nghy; gutpd; m/Nj gpj;jk;” 
  Kj;njhj;J epw;fpd; nkhoptnjd;fgNk”. 
nghUs;:- 
 ghk;G Nghy; ePz;lhy;; thj ePh; 
 Nkhjpuk; Nghy; gutpdhy; gpj;j ePh;  
 Kj;Jg;Nghy; epw;f;Fkhapd; mJ fg ePh; vd mwpayhk;. 
,yRzjhgpjj;jpy; fgj;jpw;Fhpa my;yJ gpj;jj;jpw;Fhpa my;yJ njhe;j 
Njhlj;jpw;Fhpa nea;f;FwpNah my;yJ ,ay;ghfNth ,Uf;Fk;. 
 
 
 
gpj;jfg ehb:- 
 ‘gz;ghd gpj;jj;jpy; Nrj;Jk ehb 
  ghprpj;jh yj;jpRu kpisg;G <is” 
       (rjf ehb) 
fggpj;jehb:- 
 ‘,lkhd Nrj;Jkj;jpy; gpj;jehb 
   vOe;jZfpy; tplKlNd tPf;f Kz;lhk;> 
  jplkhd Fsph; fha;r;ry; kQ;rs; NehTj; 
   Njfj;jp Yisr;rypisg; gpUky; the;jp 
  tplkhd neQ;rilg;G Rthrk; tpf;fy;  
           (rjf ehb) 
kUj;Jtk;:- 
 ‘Neha;ehb Neha;Kj dhb aJjzpf;Fk;> 
  tha;ehb tha;g;gr; nray;”. 
vd;gjw;fpzq;f> czthjp nray;fshy; cz;lhk;  Nehapid mwpAk; 
nghUl;L> Neha; mwpjw;fhd ehly; topapidf; $WJk;  m/J czT 
nray;fspd; kpFjp> Fiwthy; tsp> moy;> Iak; ,k;%d;wpy; xd;NwYk;> 
,uz;NlDk;> %d;NwDk; kpFe;J my;yJ Fiwe;J gpzpf;fg;gLkhifahy;> 
gpzpf;fg;gl;L Fw;wk; ahJ? mjw;F Kjd;ikahfapUe;jJ vJ? mjdij; 
jzpg;gjw;F top vJ? vd ehLjNy kUj;Jtdpd; ew;nrayhk;. 
          ‘cw;wh dsTk; gpzpasTq; fhyKq; 
      fw;whd; fUjpr; nray;”. 
vd;gjdhy;> Nehapdd; mile;j Fw;w NtWghLfspd; kpFjy; Fiwjy; 
msitAk;  mjdhy; NehAw;whd; ngw;w Nehapd; msitAk; (jPUk; 
 
 
jPuhnjd) mwpe;jgpd;> Nehapd; fhy msit mwpe;J> rpe;jpj;J> jFe;j 
kUj;Jtk; GhptJ mtrpak;. 
kUj;Jt topKiw:- 
 1. jd;dpiy tsh;r;rpaile;j Fw;wq;fis rkg;gLj;j Ntz;Lk;. 
 2. td;ik ,oe;j clw;fl;Lfis td;ik milar; nra;a 
kUe;jspf;f Ntz;Lk;. 
 3. Neha;fhd kUe;Jfis toq;f Ntz;Lk; 
gj;jpak;:- 
 ‘gj;jpaj;jpdhNy gyDz;lhk; kUe;J  
  gj;jpaq;fs; Nghdhy; gyd; NghFk; - gj;jpaj;jpy;  
  gj;jpaNk ntw;wpjUk; gz;bjh;f;F Mjypdhy; 
  gj;jpaNk cj;jp nad;W ghh;”. 
        -(Njiuah;) 
 kUe;Jz;Zk; fhyq;fspy; Nehahspapd; Nehapd; jd;ik nghUj;J 
czT kw;Wk; nray;fspy; MFk;. 
cz;z Ntz;bait:- 
  KUq;ifgpQ;R 
  fj;jhpg;gpQ;R 
  fz;lq;fj;jphp 
  Nga;Gly; 
  gPh;f;fk; gpQ;R 
  fPiu tiffspy; J}Jtis> fhprhiy> kzpj;jf;fhsp> 
nghd;dhq;fd;dp. 
  <Us;sp 
 
 
  mj;jpf;fha; 
,itfis Nrh;j;Jf; nfhs;syhk;. 
jtph;f;f Ntz;bait:- 
  vs; 
  nfhs;S 
  ifg;G> Gspg;G RitAs;s czTg; nghUl;fs;  
  mfj;jp fPiu 
  ghfw;fha;  
  kPd; 
  fUthL 
  Nfhop (nts;is) 
  ,dpg;G gz;lq;fs; 
  Njq;fha;  
  khq;fha; 
nray;fs;:- 
 Fsph;e;j ePhpy; jiy KOff; $lhJ. 
 Fsph;e;j jiuapy; mjpfk; <LgLjy; $lhJ. 
 ntJntJg;ghd ePhpy; cg;Gg; Nghl;L ePuhdJ njhz;ilapy; gLk;gb 
nfhg;gspf;f Ntz;Lk;. 
 
 
 
 
 
 
 
 
MODERN ASPECT 
TONSILITIS 
TONSILS AND ADENOIDS 
ANANTOMY:- 
1. Waldyer ring consists of lymphoid tissue that surrounds the opening of the 
 oral and nasal cavities into the pharynx and includes the palatine tonsils  
 the pharyngeal tonsils  (or) adenoid lymphoid tissue surrounding the 
 eustachian tube orifice in the lateral walls of the nasopharynx, the lingual 
 tonsil at the base of the tongue, and scattered lymphoid tissue throughout 
 the remainder of the pharynx but especially behind the posterior pharyngeal 
 pillars and along the posterior pharyngeal wall. 
2.  Lympoid tissue located between the palatoglossal fold (anterior tossillar 
 pillar) and the palatopharyngeal fold (posterior tonsillar pillar forms the 
 palatine tonsil. 
 This lymphoid tissue is seperated from the surrounding pharyngeal 
 musculature by a thick fibrous capsule. 
 The adenoid is a single aggregation of lymphoid tissue that occupies the 
 space between the nasal septum and the posterior pharyngeal wall. 
 A thin fibrous capsule seperates it from the underlying structures. The  
 adenoid does not contain the complex crypts that are found in the palatine 
 tonsils but rather more simple crypts. The lymphoid tissue at the base of the 
 tongue forms the lingual tonsil that  also contains simple tonsillar crypts. 
 
NORMAL FUNCTION:- 
 Approximately 65% of the lymphocytes that makeup the lymphoid tissue of 
 waldeyer ring are B lymphocytes, the remainder being either T-  
 lymphocytes . 
 The immunologic role of the tonsils and adenoid is to induce secretory 
 immunity and to regulate to production of the secretory imnunoglobulins. 
 
 
 Situated at the opening of the pharynx to the external environment, the 
 tonsils and adenoid are in a position to provide primary defense against 
 foreign matter. 
 Deep crevices within tonsillar tissue form tonsillar crysts that are lined with 
 squamous epithelium but have a concentration of lymphocytes at their 
 bases. 
 Lymphoid tissue of waldeyer ring is most immunologically active between 
 4and 10years of age, but decrease after puberty. 
 No major immunologic deficiency has been demonstrated after removal of 
 either or both of the tonsils and adenoid. 
         -Nelson  Book of 
           Paediatics 
         Page No:1756 
DEFINITION OF TONSILLITIS 
 Tonsillitis is the inflammation of the tonsils and usually occurs secondary to 
 viral (a) bacterial influenza and staphylococci. 
 On examination, the tonsils are enlarged and inflamed. Presence of follicels 
 over the tonsils indicates bacterial infection (usually streptococcal)  
 In addition there may be tender jugulodigastric lymph nodes. 
        - Achar’s Text book of  
         Pediatrics 
        ( Fourth edition ) 
EPEDIMIOLOGY:- 
 Incidence: Peak in winter and early spring  
Demographics:- 
Age:- 
 Most common in children aged  6 to 12 years, however all ages are affected. 
 Tonsilitis in children aged less than 3 years is rare and usually of viral 
 etiology . 
 
 
 
 
Gender:- 
Affects male and female population equally. 
Socioeconomic status:-  
 Further spread of infection may occur from crowded living, travelling or 
working conditions. 
 Sore throat accounts for 2.1% of ambulatory visits in the Us. Acute 
 tonsillitis is more common in children between the ages of 5 and 15 years. 
 The prevalence of bacterial tonsillitis specically group A beta hemolytic 
streptococci (GABHS) is 15% to 30% of children with score throat and 5% to 
15% of adults with sorethorat. 
 Acute tonsillitis is most commonly seen in winter and spring in temperate 
climates although it may occur at anytime of the year. 
 
ETIOLOGY:- 
 Tomsils are first line of defense against illness. 
 They produce WBC to help your body fight infection. 
 The tonsils combat bacteria and viruses that enter your body through your 
mouth. 
 However, tonsils are also vulnerable to infection from these invaders. 
 Tonsilltis can be caused by a virus, such as common cold or by a bacterial 
Infection, such as streptococcal infection.. 
 According to the American Academy of Family Physicians (AAFP) an 
estimated 15 to 30 percent of tonsilltis cases are due to bacteria. 
 Most often is it strep bacteria viruses are the most common cause of tonsils, 
The Epstein barr virus can cause tonsillitis which can also cause infective 
mononucleosis(IMN). 
 Children came into close contact with others of school and play, exposing 
them to a variety of virus and bacteria. 
 This makes them particularly vulnerable to the germs that cause tonsiiltis 
 
 
 A number of food substances can lead to tonsillitis in suscepitble 
individuals, eg: allergens such as artificial colour, flavours and 
preservatives, peanuts, cold foods, cold drinks, ice- cream and sour food. 
 Episodes of tonsillitis can also be activated by environemental changes, 
though the exact mechanisam has not been understood yet. 
 Changes  in weather, extremely cold climate, damp weather and exposure 
to pollutants can trigger episodes of tonsillitis too. 
 
PATHOLOGY:-  
 Acute Infection :- 
 Most episodes of acute pharyngo tonsillitis are casued by viruses. 
 Group A beta- hemolytic streptococcus (GABHS) is the most common 
casue of  bacterial infection in the pharyny. 
 Additional bacterial organisms can include other Beta-hemolytic 
streptocoocal (speices group C) staphylocococus aureus gram negative 
organisam Mycoplasam pneumoniea and rarely Neisseria gonorrhea and 
corynebacterium diptheriae. 
 Oral candidiasis can occur in immunocompromised patients ( or) children 
who have been treated chronically with antibitoics (or) inhaled steroids. 
 Chronic  Infection:- 
 The tonsil and adenoid can be chronically infected by multiple microbes 
which may include a high incidence of Beta- lactamase producing 
organisams. 
 Both aerobic species such as streptococci and haemophilus influenzae and 
anaerobic speices. Such as peptostreptococcus prevotella and Fuso 
bacterium predominate. The tonsillar crypts can accumulate desquamated 
epithelial cells,lymphocytes ,bacteria and other debris causing cryptic 
tonsillitis. 
 With time, these cryptic plugs can calacity into tonsillar concretions (or) 
tonsillolith . 
 
 
 
Airway obstruction :- 
 Both the tonsils and adenoid are major cause of upper airway obstruction in 
children. 
 Airway obstruction in children is typically in sleep disordered, breathing 
including obstructive sleep apnea, obstructive sleep hypopnea and upper 
airway reistance syndrome.    
 Tonsillar Neoplsam:- 
 Rapid englargement of on tonsil is highly suggestive of a tonsillar 
Malignancy, typicallay lymphoma in children. 
Tonsillor Hpertrophy Grading scale:- 
0: Tonsils fit within tonsillar fossa 
1+: Tonsils, <25% of space between pillars 
2+: Tonsils < 50 % of space between pillars 
3+: Tonsils <75% of space between pillars  
4+: Tonsils >75% of space between pillars 
CLASSIFICATION OF TONSILLITIS:-  
1. Acute Tonsilitis 
 Acute tonsillitis caused by streptococcus on hemolyticus, streptococcus, and 
streptococcus phogene can also be casued by a virus. 
2. Follicular Tonsillitis 
 Tonsils swollen and hyperemic, covered its surface is covered with patches 
of white exudates debris filling the crypts. 
 This debris contained leukocytes, eptithelial cells due to inflammation and 
remnants of food  
3. Lacunar Tonsilitis 
 Adjacent patches together and fill lacuna (curves )  surface of the tonsils 
 Membranous Tonsilitis (Septic sore Thorat) 
 Tonsillar exudates covering the surface resembles. membrane  
 These membranes  can be easily removed 
 4. chronic Tonsillitis 
 Recurrent Tonsilltis, predisposing factors: 
 
 
 
 
 
 
 
 
ACUTE TONSILLITIS:- 
 Mostly affects children in the age group of 5-15 years, may also affect adults. 
 Organisms: Beta _ hemolytic streptococci (most common) Staphylococci, 
pneumocci, H. Influnezae. 
 Symptoms: sore throat difficulty in swalwoing fever, ear ache constitutional 
symptoms. 
Types of Acute tonsililtis  
1. Acute catarrhal / Superfical here tonsiilits is a part of generalized Pharyngitis 
mostly seen in viral infections. 
2. Acute follicular - infection spread into the crypts with purulent material  
presenting at the opening of cypts as yellow spots. 
3. Acute membranous - follows stage of acute follicular tonsillitis where exudates 
coalesce to form membrane on the surface. 
4. Acute parenchymatous - tonsil is uniformly enlarged and congested 
Symptoms  
 Sore throat 
 Difficulty in swallowing 
 Generalised body ache 
 Fever   
 Earache and thick speech 
Signs 
 Swollen congested tonsils with exudates 
 Enlarged tender jugulo - diagastric lymph nodes 
 coated tongue 
 Foetid breath 
 Hyperaemia of pillars soft  palate and uvula 
Treatment:-  
 Bed Rest 
 Plenty of oral fluids 
 Analageics 
 Antimicrobial therapy - penicillin  
 
 
 In case of penicillin sentitivity  erththromcin are given  
 Antibotics should be continued for  7-10 days. 
Complications:- 
 Chronic tonsillitis 
 Peritonsillar obscess 
 para pharyngeal abscess 
 Cervical abscess 
 acute otitis media 
 Rheumatic fever 
 Acute glomerulo nephritis 
 sub acute bacterial endocarditis 
Differentail Diagnosis of membrance over the Tonsil:- 
 membranous tonsiltis 
 Diptheria 
 Vincents angina 
 Infections mononucleosis 
 Agranulocytosis 
 Leukaemia 
 Traumatic ulcer 
 Aphthous ulcer 
 Malignancy 
CHRONIC TONSILLITIS:- 
Aetiology:- 
 Complication of acute tonsiillits 
 Sub clinical infection of tonsil 
 Chronic sinusitis (or) dental sepsis 
 Mostly affects children and young adults. 
Types of CHRONIC TONSILLITIS:- 
1 Chronic Follicular tonsillitis 
 Tonsillar crypts are full of cheesy material resulting in yellow spots on the 
surface. 
 
 
2.Chronic parenchymatous tonsillitis 
 Tonsils are very much enlarged almost touching each other and may 
interferce with speech degulution and respiration long standing cases may 
develop pulmonary hypertension 
3. Chronic fibroid tonsillitis 
 Tonsils are small but infected with history of repeated sore throat  
Clinical features:- 
 Recurrent attacks of sore throat 
 Chronic irritation in throat with cough 
 Halitosis 
 Dyphagia 
 Odynophagia 
 Thick speech 
Examination:-  
 Tonsil may show varying degree of enlargement depending on the type 
 Irwin - moore sign - tonsils are small but pressure on the anterior pillar 
expresses pus or cheesy material mainly seen in fibroid type 
 There may be yellowish beads of pus on the medical surface of  tonsils - 
chronic follicular tonsillitis 
 flusing of the anterior pillar compared to rest of the pharyngeal mucosa 
 Enlargement of the jugulo- digastirc node - soft non tender 
 
Treatment:- 
Conservative management 
 Pay attenetion to the general health diet and  treatment of co- existent 
infection of teeth nose and sinuses 
Tonsillectomy:- 
 When recurrent attacks interference with speech deglutination and respiration 
Complications:- 
 Peritonsillar abscess 
 Para pharyngeal abscess 
 
 
 Retro pharyngeal abscess 
 Intra tonsillar abscess 
 Tonsillar cyst 
 Tonsillolith 
 
SIGNS AND SYMPTOMS:- 
Common signs and symptoms include 
 sore throat 
 Red, swollen tonsils 
 pain when swallowing 
 Fever 
 coughing 
 Headache 
 Tiredness 
 Chills 
 Malaise 
 White pus- filled spots on the tonsils 
 Swollen lymph nodes ( glands ) in neck  
 Pain in the ears (or) neck 
 weight loss 
 Difficulty ingesting and  swallowing meal/liquid intake 
 Difficulty sleeping 
Less common symptom include 
 Nausea 
 Fatigue 
 Stomach ache 
 vomiting 
 furry tongue 
 haltiosis 
 voice changes  
 
 
 
 Loss of appetite 
 Anxiety 
 Tonsiltoliths occur in upto 10% of the population frequently due to episodes 
of tonsillitis.  
Tonsilloliths:- 
 Tonsilloliths, also known as tonsil stones, are clusters of calcified material 
that form in the crevices of the tonsils (tonsillar crypts). While they occur most 
commonly in the palatine tonsils, they may also occur in the lingual tonsils. 
Tonsilloliths have been recorded weighing from 0.3g to 42g. They are composed 
mostly of calcium, but may contain other minerals such as phosphorus and 
magnesium, as well as ammonia and carbonate. 
 Protruding tonsillolithis may fel like foreign objects lodged in the tonsil 
crypt. They may be a nuisance and difficult to remove, but are usually not harmful. 
They are one of the causes of halitosis (bad breath). 
 While true tonsillar stones are rate, small areas of calcification or 
concretions are relatively common. 
Complications 
 Local Complications 
 Tonsillitis often resolves within three or Four days, with fever and other 
symptoms usually subsiding within a week. In some individuals however, the 
symptoms do not improve or may even worsen after this time. Some of the 
complications of Tonsillitis include 
1. Recurrent Tonsillitis 
2. Peritonsillar abscess (Quinsy) 
3. Spread of Infection 
4. Crypt Formation 
5. Breathing Difficulty 
6. Streptococcus 
7. Tonsillar cyst 
 
 
 
1.Recurrent Tonsillitis 
 In some individuals, tonsillitis occurs repeatedly every time they develop an 
 upper respiratory tract infection. This is called recurrent tonsillitis or 
 chronic tonsillitis and can severly affect a person’s daily activities. 
 Recurrent illness can also affect growth and development.  
 Chronic or recurrent tonsillitis in usually diagnosed when a person has 
 experienced one of the following. 
 At least seven episodes of tonsillitis in preceding year.  
 At least five episodes in each of the preceding two years. 
 At least three episodes in each of the preceding three years. 
2.  Peritonsillar abscess:- 
 Some people may develop an abscess several days after onset of tonsillitis 
 symptoms. Also called Quinsy, the abscess presents as a pus – filled sac 
that  forms between the wall of the throat and the back of one of the tonsils. 
3.Spread of Infection:- 
 The infection may also spread to areas around the tonsils, resulting in 
 inflammation and infection of the surrounding structures. For example, 
 bacteria present in the abscess may penetrate the nearby jugular vein, 
 infecting the blood and giving rise to septicaemia.  
 This condition is called “Lemierre’s syndrome” and can be fatal if nost 
 treated quickly and appropriately. Infection from the tonsils may also 
 spread to the middle ear resulting in otitis media or middle ear infection. 
4.Crypt Formation:- 
 The bacteria can also accumulate in the pits on the surface of the tonsils 
resulting in the formation of crypts, which produce yellow (or) white, Foul 
smelling stones called tonsilloliths.  
5. Breathing Difficulty:- 
 Recurrent tonsillitis causes the tonsils to enlarge leading to snoring, 
 disturbed sleep and mouth breathing. This is called obstructive apnea.  
 
 
 
 
6.Streptococcus:- 
 Streptococcal infection of the tonsils may lead to complications such as 
 rheumatic fever (affecting the heart valves and the joints) and 
 glomerulonephritis (Kidney infection). 
7. Tonsillar cyst:- 
 It is due to blockage of a tonsillar crypt and appears as a yellowish swelling 
 over the tonsil. Very often it is symptomless. It can be easily drained.  
Systemic complications: 
1. Glomerulonephritis 
2. Rheumatic Fever 
3. Lemierre’s syndrome 
4. Septicemia 
1. Glomerulomephritis (Very rare) is inflammation of the filters in your kidneys, 
caused by streptococcal bacteria. 
2. Rheumatic Fever 
 It is a rare condition that causes widespread inflammation through out the 
body. 
3. Lemierre’s syndrome 
 It is a rare condition in which bacteria spread form your throat to major 
veins in your neck. Small ‘clumps’ of bacteria then travel through your blood 
stream to your lungs, joints and bones. Lemierre’s syndrome can be easily treated 
with antibiotics but can be Fatal if it is not diagnosed quickly.  
4. Septicaemia  
 It can occur if bacteria get into your bloodstream and multiply. The bacteria 
can be destroyed using antibiotics.  
 
 
 
EXAMS AND TESTS 
 Diagnosis of tonsillitis is based on a medical history and a physical exam of 
the throat. An accurate medical history is needed to find out whether tonsillitis is 
recurrent, which may affect treatment choices.  
 If your symphoms suggest strep throat, we may want to confirm this 
diagnosis by doing a throat culture. strep throat is more likely if 3 or 4 of the 
following signs or symptoms are present. 
 Fever 
 White or yellow spots or coating on the throat and / or tonsils.  
 Swollen or tender lymph nodes on the neck. 
If a strep infection is suspected, we may do a rapid strep test or a throat 
culture or both. Both of these tests can be done.  
Position 
 Rose’s position, i.e, patient lies supine with head extended by placing a 
pillow under the shoulder and a rubber pad under the head. In this position 
both the Tonsils are clearly viewed.  
Advantage of Rose’s position. 
1. There is virtually no aspiration of blood or secretions into the airway. 
2. Both hands of the surgeon are free. This position helps in proper application 
of the Boyles Davis mouth gag.  
3. The surgeon can be comfortably seated at the head end of the patient. 
 
 
 
 
 
 
Treatment:- 
 Tonsillectomy is common procedure. Today, most cases of viral tonsillitis 
are managed by watching and wating (while treating the pain and fever). 
 Tonsillitis will be treated with antibiotics if bacteria appear to be the cause. 
The longer that tonsillitis last, the more likely that it will require stronger 
treatment. In some circumstances, steroids are used to reduce tonsil 
swelling.  
The American Academy of paediatrics recommends removing the tonsils 
under some conditions. 
 Tonsil or adenoid swelling that makes normal breathing difficult (this may 
or may not include sleep apnea). 
 Tonsils that are so swollen that your child has problems swallowing. 
 An enlarged adenoid that makes breathing uncomfortable, severly alters 
speech, and possibly affects normal growth of the face. In this case, surgery 
to remove only the adenoid may be recommended.  
 Your child has repeated ear or sinus infections despite treatment. In this 
case, surgery to remove only the adenoid may be recommended.  
 Your child has an excessive number of sere sore throats each year. 
 Your child’s lymph nodes beneath the lower jaw are swollen or tender for at 
least six months, even with antibiotic treatment.  
Tonsillectomy: 
 Tonsillectomy is a surgical procedure in which each tonsil is removed from 
a recess in the side of the pharynx called the tonsillar Fossa. 
 The procedure is performed in response to repeated occurrence of acute 
tonsillitis, sleep surgery for obstructive sleep apnea, nasal airway 
obstruction, diphtheria carrier state, snoring or peritonsillar abscess. 
 For children, the adenoids (also known as a pharyngeal tonsil or 
nasopharyngeal tonsil) are usually removed, a procedure called 
adenoidectomy. (or tonsilloadenoidectomy or adenotonsillectomy when 
combined). 
 
 
 Adenoidectomy is uncommon in adults in whom the adenoids are usually 
vestigial. Although tonsillectomy is performed less frequently than in the 
1950, it remains one of the most common surgical procedures in children in 
the United states.  
Indications for Removing Tonsils. 
1. Absolute 
2. Relative 
1) Absolute 
 Recurrent Tonsillitis inspite of therapy 
 Suspected malignancy 
 Obstructive sleep apnea syndrome due to adenotonsillar hypertrophy. 
2) Relative 
 Recurrent acute tonsillitis:- the number of throat infections that might 
warrant a tonsillectomy to reduce subsequent episodes remains 
controversial. Guidelines from different organizations range from three to 
seven infections per year despite medical treatment. In general, the less 
severe the history of recurrent tonsillitis, the more marginally benefit is the 
surgery. 
 Recurrent peritonsillar abscess.  
Contraindications:- 
1. Haemoglobin levels less than 10gms% 
2. Presence of acute infection in upper respiratory tract, even acute tonsillitis. 
Bleeding is more in case of acute infection. 
3. Children under three years of age. They are at poor surgical Risks.  
4. Overt or submucous cleft palate. 
5. Bleeding disorders like leukemia, purpura, aplastic anaemia, haemophilia.  
6. At the time of epidemic of polio. 
 
 
7. Uncontrolled systemic diseases eg. cardiac disease, asthma, hypertension. 
8. Tonsillectomy is avoided in the period of menses. 
RISKS FACTORS: 
 Nasal sounding voice. 
 Emotionally upset (Under 5 years of age) 
 Post – operative Infection 
 Bleeding 
Morbidity and Mortality rates: 
 Morbidity other than minor post – surgical infection is uncommon.  
 Mortality is very rare. 
PREVENTION:- 
 Tonsillectomy can prevent tonsillitis, but is only recommended in select 
circumstances.  
 Because most types of tonsillitis are spread by droplet transmission, droplet 
precautions can be effective means of prevention. 
 Take enough liquids to keep the body hydrated.  
 Eat nutritional diet includes fruits, vegetables soups.  
 Should not exposed to  passive smoking  
 Should not eat unhygienic Food and drinking contaminated water. 
  
 
 
MATERIALS AND METHODS 
CLINICAL STUDIES:- 
 After finishing the studies 40 cases were selected from the OPD and IPD of 
Kuzhanthai Maruthuram  Department, They were treated with the trail drug 
Lasunthabitha kudineer and observed for prognosis clinically. 
STUDY DESIGN AND CONDUCT OF THE STUDY:- 
Study Type  : An observational clinical study 
Study Place  : Post graduate Kuzhanthai Maruthuvam OPD and IPD  
    Government Sidhha medical college and hospital 
    Palayamkottai 
Study Peroid  : 24 months 
Sample Size  : 40 Patients ( 20 Op + 20 IP) 
 The sample consists all patients 3-12 years age group fulfilling all 
the inclusion and exclusion criteria. 
STUDY PARTICIPANTS:- 
INCLUSION CRITERIA:- 
 Age 5 to 12 years 
 Sex - Male and female children 
 Throat pain 
 Dysphagia 
 Hoarseness of voice 
  Enlarged tonsils 
  Reffered pain the Ear 
  Malaise 
 Mild fever with tonsillitis  
 
 
EXCLUSION CTITERIA 
 Congenital anomalies of pharynx 
  known case of pulmonary Tuberculosis. 
  Physilogical hyperplasia of lymphoid Follicles 
  Malignancy 
  Tonsilitis which have indication for surgery 
WITHDRAWAL CRITERIA 
 The drug not responding to the condition. 
  Intolerance to the drug and development of  adverse 
reactions during drug  trail. 
 Patient turned unwilling to continue in the course of clinical 
trail. 
  Occurrence of any serious illness 
TERMINATION CRITERIA 
     Not reporting subsequently 
     Voluntary termination 
TESTS AND ASSESMENTS 
 Clinical assessment 
  Siddha  methodological assessment  
 Laboratory Investigation* Imaging assessment 
CLINICAL ASSESSMENT:-  
 Throat pain 
  Dysphagia 
  Hoarsenoss of voice 
  Enlarged tonsils 
  Malaise 
  Mild fever with tonsillitis 
 
 
  Reffered pain in ear 
 Oedema of uvula and congestion   
SIDDHA TESTS AND ASSESSMENTS:- 
I. UDAL KATTUKAL 
Saram 
senner 
OOnn 
Kozhuppu 
Enbu 
Moolai 
Sukkilam/suronitham 
II ENVAGAI THERVU 
Naadi 
Sparisam 
Naa 
Niram 
Mozhi 
vizhi 
Malam 
Moothiram 
 
 
 
 
III NEERKURI 
IV NEIKURI 
INVESTIGATION:- 
 Blood : TC, DC, ESR, HB, Total RBC Count, Absolute Eosinophil  
   count 
 Urine : Albumin, sugar, Deposits 
  Motion : Ova, cyst 
SPECIAL INVESTIGATIONS:- 
 Thorat  swab culture 
  ASO TITRE ( group A  haemolytic streptococcus) 
METHODOLOGY OF TREATMENT:- 
 Study Enrolment:-  
 Patient reporting at the OPD  associated with clinical Features of 
 Throat pain 
  Diffiuclty in swallowing 
  Difficulty in Speaking 
 Mild fever with tonsillitis 
 General tiredness 
  Pain in the Ear 
are choosen for enrollment based on the inclusion criteria 
The patient’s parents/ guardian who are informed ( Form IV ) about the study trial 
drug. post outcomes and the objectives of the study in the language and terms 
understandable to them and the informed conset would be obtained in writing form 
them in the consent form ( From IV)  
 
 
 
CONDUCT OF THE STUDY:- 
 The trail drug will be given in  the OPD Department of Kuzhanthai 
Maruthvam GSMC Playamkottai. The patients will be asked to have a regular 
follow up in the Op department once in 2 days. In each and every visit the clinical 
assessment will be recorded in the  prescribed proforma, The latoratory 
investigation will be done before and after treatment and recorded in the prescribed 
format. 
DATA MANAGEMENT:- 
 After enrolling the patients in the study, a separate file for each patient will 
be maintained and all forms will be kept in the file. Whenever the patient visits 
OPD during the study period, necessary entires will be made at the assessment 
forms. data recordings and adverse events, of any,will be mointored by the Head of 
the Department and Pharmacovigilance committee. 
OUTCOME:- 
Primary Outcome:- 
 Primary outcome is mainly assessed by comparing the reduction in clinical 
symptoms are recurrence before and after treatment.  
Secondary Outcome:- 
 Secondary outcome is assessed by comparing the safety  Parameters before 
and after treatment 
PROGNOSTIC CRITERIA 
GRADE I : showed good improvement 
GRADEII :Symptoms moderately reduced 
GRADEIII   : Symptoms slightly reduced 
GRADE IV : No imporovement 
 
 
ADVERSE EFFECT/ SERIOUS EFFCET MANAGEMENT:- 
 If the trail patient develops any adverse reaction he/she would be 
immediately withdrawn form the trail and proper managemet will be given in OPD 
of Govt. Sidhha medical college and hospital Palayamkottai. 
ETHICAL ISSUES:- 
1.  To prevent any infection while collecting blood samples from the patient, 
 only disposable syringes, disposable gloves with proper sterilization of 
 laboratory equipments will be used. 
2.  There will be no infringement on the rights of patient. No other enternal or 
 internal medicines will be used other than the trail drug in  the treatment 
 course of lasuthabitham there will be no infringement on the rights of the 
 patient. 
3. The data collected from the pateints’s parents/guardian will be kept 
 confidential 
4.  The patient’s parents / guardian will be informed about the disease and 
 other details of the treatment. 
5.  After obtaining the written consent of the patients’s Parents guardian 
 (through  consent of the patient’s parnts) guardian ( through consent form in 
 their vernacular language ) they will be enrolled in the study. 
6.  Treatment would be provided free of cost. 
7.  In case of any adverse rections,the patients will be referred to the OPD of 
 Kuzhanthai Maruthavam department of Govt, Siddha medical College 
 hospital Palayamkottai for  further management. 
8.  The patient will be allowed to withdraw form this trail if their parents/ 
 guardian are not satisified with this treatment and procedures.  
 
 
 
DRUG REVIEW 
PREPARATION AND PROPERTIES OF TRIAL  DRUG 
,yRzjhgpjf; FbePH (cl;gpuNahfk;) 
,yRzjhgpjf; FbePH: 
  ‘.................................... KUq;ifj;Njhw; 
   rptd;Ntk;Ge; jdpNtk; gpd;Nwhw; 
  rq;fjpd;Nwhyhjz;ilf; flhaj;Js; 
   ntq;fhue; jhf;fpf;nfhs;Ns”. 
NrUk; ruf;Ffs;: 
1. KUq;ifg;gl;il (Moringa oleifera) 
2. rptdhHNtk;GNtHgl;il (Indigofera aspalathoides) 
3. rq;fk;NtHgl;il (Azima tetracantha) 
4. Ntg;gk;gl;il (Azadirchta indica) 
5. Mnjhz;il (Capparis zeylanica) 
nra;Kiw:- 
 ruf;Ffis ed;whf Rj;jp nra;J> xd;wpuz;lhf ,bj;J> xU 
ghj;jpuj;jpy; 120kpyp jz;zPH Cw;wp ,bj;J ruf;Ffspy; 10 fpuhk; 
vLj;Jg;Nghl;L> mjid fha;r;rp 30kpyp tUk; tiu tw;witj;J> tbf;fl;b 
nfhs;sTk;.  
msT:- 
 3 – 5 taJ – 10 kpyp  
 6 – 8 taJ – 20 kpyp  ,U Ntis czTf;F Kd; 
 9 – 12 taJ – 30 kpyp 
 
 
 
mDghdk;: 
 nghhpj;j ntq;fhuk; - 50 - 100kpfp (Nkk;nghbahf J}tp frhaj;Jld; 
fye;J jug;gl;lJ) 
msT ehs;:- 8 (8f;F Nkw;gl;l ehl;fs;) 
gj;jpak;:- 
 ifg;G> Gspg;G ePf;fg;gl Ntz;Lk;.  
E}y; Mjhuk;: 
 tpuz fug;ghd; Nuhf rpfpr;ir 
 (ruNge;jpu itj;jpa Kiwfs;) gf;fk; vz;. 137>138 
E}y; MrphpaH: 
 kU. S. ntq;fl;luh[d; L.I.M mtHfs; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROPERTIES OF TRIAL MEDICINE 
 
1. rptdhHNtk;G NtHgl;il: 
Botanical Name : Indigofera aspalathoides 
Family  : Fabaceae. 
Rit          : ifg;G 
jd;ik         : ntg;gk; 
gphpT          : fhHg;G 
nra;if         : ntg;gKz;lhf;fp – Stimulant 
   cs;soyhw;wp – Demulcent 
Chemical Constituents:- 
 ,e;j nrbapy;  
 Flavonoides 
  Alkaloids 
  Phenols 
  Terpenoids 
 Steroids 
 Tannins 
  Saponins 
  Glycosides  
 Proteins cs;sJ. 
2. KUq;ifg;gl;il: 
 Botanical Name :  Moringa oleifera 
 Family  : Moringaceae 
 Rit   : ifg;G> JtHg;G> ,dpg;G 
 jd;ik  : jl;gk; 
 gphpT   : fhHg;G 
 nra;if  : Nfhioafw;wp – Expectorant 
     ,rptfw;wp – Antispasmodic 
     ntg;gKz;lhf;fp – Stimulant 
 
 
 
 NtHgl;ilahy; IaKk;> Kg;gpzpAk; 
 gl;ilahy; tspf;Fw;wKk;> rpy eQ;RfSk; jPUk;.  
Chemical Constituents:- 
 Alkaloids  Moringine 
   Moringinine 
  Saponins 
  Tannins 
 Steroids 
 Triterpenoids 
 Tannins 
 
3. Ntg;gk;gl;il: 
 Botanical Name :  Azadirachta indica 
 Family  :  Meliaceae 
 Rit   : ifg;G> rpW JtHg;G 
 jd;ik  : ntg;gk; 
 gphpT   : fhHg;G 
 nra;if  : Kiw ntg;gfw;wp – Antiperiodic 
     cukhf;fp – Tonic 
     JtHg;gp - Astringent 
Chemical Constituents:-    
 Azadirachtin .A 
  Azaridine 
 Terpenoids   
  Alkaloids 
   Glycosides 
    Beta Sitosterol 
     Nimbinene 
     Nimbin 
 
 
 
 
 Nimbiol 
 Nimocin 
 Nimbolide 
 Quercetin 
 n – hexacosanol 
 Isomeldenin 
 Azadiractol  
 Azadirachnol 
 Ia Ruk; Kjypa Ruq;fs;> Ruj;jhYz;lhFk; cly; jsh;r;rp NghFk; 
4. rq;fk;Nth;gl;il 
Botanical Name  : Azima tetracantha 
Family   : Salvadoraceae 
Rit    : ifg;G 
jd;ik   : ntg;gk; 
gphpT    : fhh;g;G 
nra;if   : Nfhiofw;wp  - Expectorant 
     cukhf;fp  - Tonic 
     ntg;gKz;lhf;fp - Stimulant 
     Kiwntg;gfw;wp - Antiperodic 
Chemical Constituents 
 Alkaloids 
 Carpine 
 Azimine 
 Piperidine 
 Friedelin 
 
 
 Lupeol 
 Beta sterol from the petroleum etler extract of the roots this plant. 
 Recently Daultabad eta 
 7H Obtained novel fatty acids such as ricinobeicacid 9.8% 
sterculic acid 5.6% along with  other fatty acids such as lauric 
3.5% myistic acid (4.2%) palmitric acid  (5.2%) stearic acid 1.6% 
 Steroids 
 Carbohydrates 
  Reducing sugars 
 Riterpinods 
 Phenolic compounds 
 Saponin 
 Xantho proteins 
 Tannins 
 Flavonoids 
5.M njhz;il 
  Botanical name  : Capparis zeylanica 
  Family  : Capparaceae 
  Rit   : rpWifg;G 
  jd;ik  : ntg;gk; 
  gphpT   : fhh;g;G 
  nra;if  : jhJntg;gw;wp - Sedative 
      grpj;jPj;jhz;b - Stomachic 
 
 
 
 
 
Chemical Constituents:- 
 Flavanoids 
 Fatty acids 
 Lipids   
 alkaloids 
 Glucosinolates 
 Vanillic acid 
 Ferulic acid 
 P-coumarric acid 
 Phytosterols 
 Alkaloids 
 %f;filg;G> njhz;ilapw; NrUk; rsp>Filr;ry; Kjypait jPUk;. 
 M njhz;ilf;fhia tw;wyhf;fp czTld; Nrh;j;J cz;zpy; Ia 
Neha; $l;lq;fs; ahTk; ePq;Fk;. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mDghdk; 
ntq;fhuk;: 
  Chemical Name :sodium biborate 
  Rj;jp : kzprl;bapy; ePh;gjk; NghFk; tiu nghhpj;J vLj;jy;  
  ‘nrhwpGil naz;Fd;k ed;ik nrhpaurk; 
    awpfpuzp fy;Yhdk; gd;Ndha; njwpiar; 
    jlq;fzq;f kq;fpUep rh;tplQ; re;jp 
    aplq;fzq; fyr;rpk;Ngh nkz;” 
nghUs; :- 
 ntq;fhuj;jpdhy; jtisr; nrhwp> gil> m\;lFd;kk;> jpdT> 
gpj;j%yk;> xOf;Ffpuhzp> m];khhp gq;Fthjk;> je;jNeha;> ehstopia 
jLf;fpd;w %j;jpuf;fphpr;ruq;fs; fghjpf;fk;> ghk;G GUtplk; re;jpghjk; 
Mfpait jPUk;. 
 
 
 
 
 
 
 
 
 
 
 OBSERVATION AND RESULTS 
1. AGE DISTRIBUTION. (Table No: 1) 
S.No Age 
No. Of cases 
(out of 40) 
Percentage 
(%) 
1 
0-1 year 
Kappu and Chenkeerai 
- - 
2 
2 year – 3 year 
Varugai, Thalattu, Sappani, Mutham - - 
3 
 
 
4 years – 6 years 
Ambuli, Chitril, Chiruparai, 
Chiruthervidhal, Paethai (female) & Pillai 
(male) paruvam 
14 35 
4 
7 years – 10 years 
Paethamai (female) 
Chiruparuvam (Male) 
14 35 
5 11 years – 12 years 
Mangai (Female), Valibam (Male) 
12 30 
 
AGE DISTRIBUTION 
 
 
                           Children under the age group of 7 yrs to 10 yrs were commonly 
affected. Among school going age group, overcrowding of children had high 
incidence of tonsillar infection. 
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 2. SEX - DISTRIBUTION: (Table No: 2 ) 
 
S.No Sex No. of cases (out of 40) Percentage(%) 
1 
Female 
Children 
24 60 
2 
Male 
Children 
16 40 
  
 
 
 
Among 40 cases studied  16 were male Children (40%) and 24 were female 
Children (60%). Though in the author’s study to female child was highly affected 
than males, there is no apparent sex prediction. 
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 3. SOCIO-ECONOMIC STATUS: (Table No: 3) 
S.No Socio-economic status No. of cases (out of 40) Percentage (%) 
1 Poor 26 64 
2 Middle Class 10 26 
3 Rich 4 10 
 
 
 
                   According to this study 26 cases of  Poor socio economic  status  was 
noticed, this was due to lack of nutritious food and unhygienic condition and 10 
belongs to Middle class, 4 belongs to Rich. 
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S.No Paruvakaalam
1 Kaar (Aavani, Purattasi)
2 Koothir 
(Ayppasi, Karthigai)
3 Munpani 
(Markazhi, Thai)
4 Pinpani (Maasi, Pankuni)
5 Ela Venil 
(Chithirai, Vaikasi)
4. DISTRIBUTION OF PARUVA KALANGAL (Table No: 4) 
S.No Paruvakaalam No. of cases (Out of 40) Percentage (%) 
1 Kaar (Aavani, Purattasi) - - 
2 Koothir (Ayppasi, Karthigai) - - 
3 Munpani (Markazhi, Thai) 16 40 
4 Pinpani (Maasi, Pankuni) 17 42.5 
5 Ela Venil (Chithirai, Vaikasi) 7 17.5 
6 Muthuvenil (Aani, Aadi) - - 
 
 
DISTRIBUTION OF PARUVA KALANGAL 
 
 
 
 
 
 
 
 
 
 
 
 
 Lasunathabitham was more common during winter i.e., Munpani, Pinpani, 
Elavenil kaalam. In Elavenil kaalam kabham gets vetrunilai valarchi,intake of sour 
taste and sugar taste induces kabha kuttram, action inducing the vitiation of kabha 
kutram produces symptoms of Lasunathabitham. 
 
 
 
 
 5. DIET HISTORY  (Table No: 5) 
 
S. No Type of Diet No. of cases (Out of 40) Percentage(%) 
1 Vegetarian 5 12.5 
2 Mixed 35 87.5 
 
 
 
 
 According to diet, high incidence of cases 87.5% was noted in mixed diet 
and in vegetarian 12.5% cases are noted.   
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6. FAMILY HISTORY  (Table No:6) 
 
S. No FAMILY HISTORY No. of cases (Out of 40) Percentage(%) 
1 Positive Family History 4 12 
2 Negative Family History 36 88 
 
 
FAMILY HISTORY 
 
 
 
 
 
 
 
 
 
  
 
 
 Out of 40 cases 36 (88%) cases have negative family history and 4 (12%) 
cases have positive family history. 
 
 
 
 
 
 
 
 
 7. DISTRIBUTION OF LANDS: (Table No: 7) 
S. No Distribution Of Lands No. of cases (Out of 40) Percentage(%) 
1 Kurinji (hill) - - 
2 Mullai ( forest) - - 
3 Marutham (fertile) 39 97.5 
4 Neithal ( coastal) 1 2.5 
5 Paalai ( desert) - - 
 
DISTRIBUTION OF LANDS 
 
 
According to the Siddha concept, Marutha Nilam does not produce any 
disease among the people residing in the land. But due to altered life style and 
environmental conditions the incidence of lasunathabitham occurs in land of 
Marutham and Neithal.Tirunelveli belongs to Marutha nilam and the people in and 
around were affected by this disease. Therefore, there is no apparent thinai 
prediction for this disease. 
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DERANGEMENT OF VATHAM
S.No Types of Vatham
S.No Types of Vatham
1 Pranan (gpuhzd;)
2 Abanan (mghdd;)
3 Viyanan (tpahdd;)
4 Uthanan (cjhdd;)
5 Samanan ( rkhdd;)
6 Naagan (ehfd;)
7 Koorman ($h;kd;)
8 Kirukaran (fpUfud;)
8. MUKKUTRA THEORY: (Table No: 8) 
1. DERANGEMENT OF VATHAM:- 
S.No Types of Vatham 
No. of cases 
(Out of 40) 
Percentage(%) 
1 Pranan (gpuhzd;) 40 100 
2 Abanan (mghdd;) 8 20 
3 Viyanan (tpahdd;) 30 75 
4 Uthanan (cjhdd;) 40 100 
5 Samanan ( rkhdd;) 40 100 
6 Naagan (ehfd;) - - 
7 Koorman ($h;kd;) - - 
8 Kirukaran (fpUfud;) 10 25 
9 Devathathan (Njtjj;jd;) 30 75 
10 Dhananjeyan(jdQ;nrad;) - - 
 
 
 
 
 
 
 
 
 
 
 
 
In vatham, all cases had derangement in Pranan, Uthanan, Samanan, In 75% 
of cases Viyanan, are affected. Kirukaran was affected.25% of cases, Devathathan 
was affected.75%,  20% Abanan affected. 
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2. DERANGEMENT OF PITHAM:  
S.No Types of Pitham 
No. of cases  
(out of 40) 
Percentage(%) 
1 Anailapitham (mdpygpj;jk;) 25 62.5 
2 Ranjakam (,uQ;rfk;) 30 75 
3 Saathakam (rhjfk;) 30 75 
4 Pirasakam (gpuhrfk;) - - 
5 Aalosakam (MNyhrfk;) - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Pitham, Sathagam  and Ranjagam was affected in 75% of cases. In 
Avalampagam 62.5%  of patients were affected. 
 
 
 
 
 
 
 
 
 3. DERANGEMENT OF KABAM:  
S.No Types of Kabam 
No. of cases  
(out of 40) 
Percentage (%) 
1 Avalambakam (mtyk;gfk;) 40 100 
2 Kilethakam ( fpNyjfk;) 15 37.5 
3 Pothakam (Nghjfk;) 10 25 
4 Tharpakam ( jw;gfk;) 20 50 
5 Santhikam ( re;jpfk;) - - 
 
 
 
 
 
In kapham, Avalampagam was affected in all the patients.50% of patients 
were affected by Tharpagam, 37.5% of patients were affected kilethagam, In 
Bothagam 25% patients were affected. 
 
 
 
 
 
 
0%
20%
40%
60%
80%
100%
1 2
DERANGEMENT OF KABAM
5 Santhikam ( re;jpfk;)
4 Tharpakam ( jw;gfk;)
3 Pothakam (Nghjfk;)
2 Kilethakam ( fpNyjfk;)
1 Avalambakam 
(mtyk;gfk;)
S.No Types of Kabam
 9. UDAL KATTUGAL: (Table No: 9) 
 
S.No UDAL KATTUGAL 
No. of cases  
(out of 40) 
Percentage (%) 
1 Saaram (rhuk;) 40 100 
2 Senneer ( nre;ePh;) 35 87.5 
3 Oon ( Cd;) 40 100 
4 Kozhuppu (nfhOg;G) - - 
5 Enbu ( vd;G) - - 
6 Moolai ( %is) - - 
7 Sukkilam / Suronitham  
(Rf;fpyk; / RNuhzpjk;) 
- - 
  
 
UDAL KATTUGAL 
 
 
The first Thadu Saaram was affected in all the patients because of increased 
kabham.Involvement of Seneer caused increased ESR and  Oon caused the 
enlargement of the gland. 
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 10. ENN VAGAI THERVUGAL: (Table No: 10) 
S.No Enn Vagai Thervugal No. of cases (out of 40) Percentage (%) 
1 Naadi (ehb) - - 
A Vatha Pitham 9 22.5 
B Pitha Kabam 17 40 
C Vatha Kabam 2 5 
D Kaba Pitham 12 30 
2 Sparisam 15 37.5 
3 Naa 12 30 
4 Niram 15 37.5 
5 Mozhi 25 60 
6 Vizhi 15 37.5 
7 Malam 10 25 
8 Moorthiram 10 25 
 
ENN VAGAI THERVUGAL 
 
 
In ennvagai thervugal  pale appearance and white coating of tongue, dull 
voice,redness of eyes, fever, and burning micturation were noticed  respectively.  
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11. NEI KURI:  (Table No: 11) 
S.No 
Neikuri 
Reference 
Characters of Urine 
No. of cases 
(out of 40) 
Percentage 
(%) 
1 Vatha Neer Spreads like Snake 4 10 
2 Pitha Neer Spreads like RING 6 15 
3 Kaba Neer Spreads like PEARL 30 75 
 
NEI KURI  
 
 
             
 
 
 
 
   
 
  
 
 Among the 40 cases, 30 cases were observed Kabha neer , 6 cases Pitha 
neer and 4 case Vatha neer. 
 
 
 
 
 
 
 
 
 
 
  
12. AETIOLOGICAL FACTORS OF LASUNATHABITHAM (Table No: 12) 
 
S.No Aetiological factors No. of cases 
(Out of 40) 
Percentage 
(%) 
1 Intake of cold food stuffs, cool drinks, Ice 
creams etc., 
35 87.5 
2 Drinking contaminated water 25 62.5 
3 Seasonal Variations 35 87.5 
4 Family History 10 25 
5 Living in congested areas, using same 
vessels by many. 
30 75 
 
AETIOLOGICAL FACTORS OF LASUNATHABITHAM 
 
             From the study, the author concludes that the main cause for the 
occurrence of Lasunathabitham was intake of cold food stuffs like ice creams and  
Drinking of contaminated water. Seasonal variations, Living in congested areas, 
Family history are other causes of Lasunathabitham. 
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13. CLINICAL FEATURES - SIGNS AND SYMPTOMS (Table No: 13) 
 The signs and symptoms of patients with Lasuna thabitham under the 
clinical study was given below 
S.No Clinical features 
No. of cases 
(Out of 40) 
Percentage
(%) 
1 Sore throat 40 100 
2 Cough  38 95 
3 Fever 15 37.5 
4 Nausea 5 12.5 
5 Earache 8 20 
6 Halitosis 5 12.5 
7 Constipation 10 25 
8 Dysphagia 35 87.5 
9 Nasal congestion & Nasal Discharge 20 50 
10 Distaste 10 25 
11 Hoarseness of voice 35 87.5 
12 Headache 4 10 
13 Redness and swelling of the tonsil 40 100 
14 Cervical Lymphadenitis 30 75 
 
 
  
  
 
 
 
 
 
 
 
 
 Most of the patients had sore throat, cough, fever, dysphagia, anorexia, 
malaise, redness and swelling of the tonsil with cervical lymphadenitis were noted. 
Most of the symptoms and signs were relived after the treatment. 
 14.RESULTS AFTER TREATMENT (TOTAL) (Table No. 14) 
S.No Result No. of cases (Out of 40 ) Percentage (%) 
1. Good 29 72.5 
2. Moderate 8 20 
3. Mild 3 7.5 
 
 
  
 
 
72.5 % (29 cases) showed good results,  (8 cases)20% showed Moderate 
results and 7.5% (3 cases) showed mild response. These results based on the 
clinical improvement. 
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INVESTIGATIONS OF 20 IN PATIENTS OF LASUNATHABITHAM 
S
SL. 
NO. 
IP NO. Name of the Patient 
HEMATOLOGICAL INVESTIGATIONS 
Before Treatment  After Treatment 
TCL 
Cumm 
DC % ESR mm HB 
gms 
% 
TCL 
Cumm 
DC % ESR mm HB 
gms 
% P L E 
½ 
hr 1 hr P L E ½ hr 1 hr 
01.  152 Sandhiya 8400 53 40 7 2 5 12 8300 54 42 4 2 4 12 
02.  293 Chrishma 8000 55 31 14 9 18 11.6 8000 59 33 8 6 12 11.8 
03.  259 Maragatham 7900 60 34 6 3 6 10.2 7800 58 40 2 3 6 10.4 
04.  751 Harini 8400 49 38 13 3 7 10.7 8400 54 39 7 2 4 10.9 
05.  889 Abishika 9000 54 44 2 9 18 9.8 8900 56 41 3 7 14 9.8 
06.  437 Keerthi 8600 53 43 4 4 8 10.2 8500 53 43 4 3 6 10 
07.  488 Saravanan 8000 47 29 24 8 15 9.4 7900 49 36 15 5 10 9.5 
08.  529 Muhammed 7800 51 45 4 5 10 11 7800 52 46 2 3 6 10.8 
09.  536 Sathiya 8200 53 35 12 8 16 11.3 8100 56 37 7 4 8 11.2 
10.  584 Visalini 7900 67 30 3 3 6 10.8 7900 64 32 4 3 6 10.8 
11.  585 Senbagavalli 8500 61 34 5 2 4 12 8400 61 35 4 2 4 11.6 
12.  599 Krishna 7300 56 38 6 8 16 10.4 7200 58 39 3 5 10 10.8 
13.  642 Maharaja 7600 55 41 4 3 6 9.5 7600 56 42 2 2 4 9.5 
14.  647 Kadhar Meer 8100 64 31 5 5 10 11.3 8000 64 33 3 4 8 11.5 
15.  648 Jerina 9100 48 38 14 11 22 10 9000 54 38 8 7 14 10.2 
16.  690 Dharshan 7500 67 25 8 2 4 12 7400 66 30 4 2 4 12 
17.  704 Priya 8800 65 29 6 6 13 10.9 8700 64 32 4 4 8 11 
18.  1059 Malliga 8400 59 39 2 3 6 9.1 8400 57 41 2 2 4 9.4 
19.  1077 Sankar 8700 53 34 13 5 10 11.8 8600 55 38 7 3 6 11.6 
20.  1079 Stella 7600 53 38 9 8 16 10.4 7600 56 41 3 6 12 10.6 
 
 
 
INVESTIGATIONS OF 20 IN PATIENTS OF LASUNATHABITHAM 
SL. 
NO. 
I
IP 
NO. 
Name of the 
Patient 
URINE ANALYSIS MOTION ANALYSIS 
Before Treatment After Treatment Before Treatment After Treatment 
Alb Sug Dep Alb Sug Dep Ova Cyst Ova Cyst 
1.  1152 Sandhiya Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
2.  2293 Chrishma Nil Nil 
1-2 Epilhelial 
cells Nil Nil NAD Nil Nil Nil Nil 
3.  2259 Maragatham Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
4.  7751 Harini Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
5.  8889 Abishika Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
6.  4437 Keerthi Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
7.  4488 Saravanan Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
8.  5529 Muhammed Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
9.  5536 Sathiya Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
10.  5584 Visalini Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
11.  5585 Senbagavalli Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
12.  5599 Krishna Nil Nil 1-2 pus cells Nil Nil NAD Nil Nil Nil Nil 
13.  6642 Maharaja Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
 
 
14.  6647 Kadhar Meer Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
15.  6648 Jerina Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
16.  6690 Dharshan Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
17.  7704 Priya Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
18.  111059 Malliga Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
19.  111077 Sankar Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
20.  111079 Stella Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
 
 
 
 
 
 
 
 
 
 
 
 
Case Report of 20 In Patents of Lasunathabitham 
S.No IP. 
No 
Name Age/ 
Sex 
Duration of 
Illness 
(Days) 
Signs and Symptoms Admission 
Date 
Discharge 
Date Results 
1 152 Sandhiya 6FC 8 
Cough, Fever  Throat Pain, Redness and 
Swelling, Cervical adenitis, 
Nasalcongestion, Dysphagia, Constipation 
23.01.16 30.1.16 Good 
2 293 Chrishma 6FC 20 
Cough, Fever  Throat Pain, Redness and 
Swelling, Cervical adenitis, 
Nasaldischarge, Dysphagia, Nausea, Voice 
Changes 
03.02.16 13.02.16 Moderate 
3 259 Maragatham 
11F
C 8 
Cough, Fever  Throat Pain, Redness and 
Swelling, Cervical adenitis, 
Nasaldischarge, Distaste Dysphagia, , 
Voice Changes 
01.02.16 09.02.16 Good 
4 751 Harini 5FC 10 
Cough, Fever  Throat Pain, Redness and 
Swelling, Cervical adenitis, 
Nasaldischarge, Distaste Dysphagia, , 
Voice Changes Constipation 
19.03.16 26.03.16 Good 
5 889 Abishika 5FC 15 
Cough, Fever  Throat Pain, Redness and 
Swelling, Cervical adenitis, 
Nasaldischarge, Distaste Dysphagia, , 
Voice Changes  
01.04.16 08.04.16 
Moderate 
 
 
6 437 Keerthi 6FC 14 
Cough, Fever  Throat Pain, Redness and 
Swelling, Cervical adenitis, Distaste 
Dysphagia, , Voice Changes Constipation, 
Bad smell in mouth 
18.02.16 22.02.16 
 
Good 
 
 
 
7 488 Saravanan 8MC 10 
Cough, Throat Pain, Redness and Swelling, 
Cervical adenitis, Nasalcongestio, Distaste 
Dysphagia, , Voice Changes Constipation, 
Nausea 
24.02.16 03.03.16 Good 
8 529 Muhammed 10MC 14 
Cough, Throat Pain, Redness and Swelling, 
Cervical adenitis, Nasalcongestio, Distaste 
Dysphagia, , Voice Changes Bad smell in 
mouth 
27.02.16 04.03.16 Moderate 
9 536 Sathiya 8FC 7 
Cough, Fever, Throat Pain, Redness and 
Swelling, Cervical adenitis, 
Nasalcongestio, Distaste Dysphagia, , 
Voice Changes Distaste 
28.02.16 05.03.16 Good 
10 584 Visalini 12FC 7 
Cough, Fever  Throat Pain, Redness and 
Swelling, Cervical adenitis, 
Nasaldischarge, Dysphagia,  Voice 
Changes, Constipation, Bad smell in mouth 
Ear Pain 
03.03.16 09.03.16 Moderate 
11 585 Senbagavalli 10FC 8 
Cough, Fever  Throat Pain, Redness and 
Swelling, Cervical adenitis, 
Nasaldischarge, Dysphagia,  Voice 
Changes, Constipation, Bad smell in mouth 
Ear Pain Distaste 
03.03.16 10.03.16 Good 
12 599 Krishna 10MC 7 
Cough, Fever  Throat Pain, Redness and 
Swelling, Cervical adenitis, 
Nasaldischarge, Dysphagia,  Voice 
Changes, Constipation, Bad smell in mouth 
Ear Pain Distaste Wheezing frequently 
05.03.16 12.03.16 
 
Mild 
 
13 642 Maharaja 4 ½ MC 15 
Cough, Fever  Throat Pain, Redness and 
Swelling, Cervical adenitis, 09.03.16 15.03.16 Good 
 
 
Nasaldischarge, Dysphagia,  Voice 
Changes, Constipation, Bad smell in mouth 
Ear Pain Distaste Wheezing frequently 
14 647 Kadhar Meer 
11 
FC 14 
Cough,  Throat Pain, Redness and 
Swelling, Cervical adenitis, Nasal, 
Congestion  Dysphagia,  Voice Changes, , 
Bad smell in mouth, Distaste  
09.03.16 17.03.16 Good 
15 648 Jerina 12 FC 14 
Cough, Fever  Throat Pain, Redness and 
Swelling, Cervical adenitis, Nasal 
Congestion, Dysphagia,  Voice Changes, 
Constipation, Headache 
09.03.16 16.03.16 Good 
16 690 Dharshan 5 MC 25 
Cough, Fever  Throat Pain, Redness and 
Swelling, Cervical adenitis, Dysphagia,  
Voice Changes, Nausea, Vomiting, Ear 
Pain Distaste 
14.03.16 22.03.16 Good 
17 704 Priya 8 FC 14 
Cough,   Throat Pain, Redness and 
Swelling, Cervical adenitis, Nasal 
Congestion, Dysphagia,  Voice Changes, 
Constipation,  
15.03.16 28.03.16 Good 
18 1059 Malliga 4 ¾ FC 30 
Fever   Throat Pain, Redness and Swelling, 
Cervical adenitis, Distaste Dysphagia,  
Voice Changes, Constipation, 
20.04.16 28.04.16 Good 
19 1077 Sankar 8 MC 10 
Cough,   Throat Pain, Redness and 
Swelling, Cervical adenitis, Dysphagia,  
Voice Changes, Badsmell in mouth 
21.04.16 29.04.16 Good 
20 1079 Stella 8 FC 7 
Cough, Fever, Headache  Throat Pain, 
Redness and Swelling, Cervical adenitis, 
Nasal Congestion, Dysphagia,  Voice 
Changes, Constipation, 
21.04.16 30.04.16 Good 
 
 
 
                      
 
      THROAT SWAB  CULTURE 
    Before Treatment After Treatment 
SL. 
No 
IP.No Name Age/ 
Sex 
Present Organisms in 
Culture 
Present Organisms 
in Culture 
1 152 Sandhiya 6FC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
2 293 Chrishma 6FC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
3 259 Maragatham 11FC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
4 751 Harini 5FC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
5 889 Abishika 5FC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
6 437 Keerthi 6FC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
7 488 Saravanan 8MC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
8 529 Muhammed 10MC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
9 536 Sathiya 8FC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
10 584 Visalini 12FC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
11 585 Senbagavalli 10FC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
12 599 Krishna 10MC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
13 642 Maharaja 4 ½ MC 
Staphylococcus, 
Streptococcus, Pneumococcus 
Nil 
14 647 Kadhar Meer 11 FC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
15 648 Jerina 12 FC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
16 690 Dharshan 5 MC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
17 704 Priya 8 FC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
18 1059 Malliga 4 ¾ FC 
Staphylococcus, 
Streptococcus, Pneumococcus 
Nil 
19 1077 Sankar 8 MC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
20 1079 Stella 8 FC Staphylococcus, Streptococcus, Pneumococcus 
Nil 
 
 
ABSOULTE EOSINOPHIL COUNT 
S.NO. IP 
NO. 
NAME AGE / 
SEX 
AEC (BT) AEC (AT) 
1)  751 Harini 5 FC 1070 Cells / 
cumm 
400 cells / 
cumm 
2)  690 Dharshan 5 MC 600 cells 320 cells 
3)  704 Priya 8 FC 510 cells 290 cells 
4)  642 Maharaja 4 ½ MC 280 cells 260 cells 
5)  647 Kadhar 
Meera 
11 FC 390 cells 330 cells 
6)  584 Vishalini 12 FC  250 cells 250 cells 
7)  293 Chrisma 6 FC  980 cells 370 cells 
8)  889 Abishika 5 FC 200 cells 210 cells 
9)  599 Krishna 10 MC 8.00 cells 340 cells 
10) 1079 Stella 8 FC 530 cells 310 cells 
 
 
 
INVESTIGATIONS OF 20 OUT PATIENTS OF LASUNATHABITHAM 
 
SL. 
NO. 
OP NO. Name of the Patient 
HEMATOLOGICAL INVESTIGATIONS 
Before Treatment  After Treatment 
TCL 
Cumm 
DC % ESR mm HB 
gms 
% 
TCL 
Cumm 
DC % ESR mm HB 
gms 
% P L E 
½ 
hr 1 hr P L E 
½ 
hr 1 hr 
1.  109304 Divya 8100 51 45 4 3 6 11 8000 55 45 3 3 6 0.8 
2.  109258 Muhatheswaran 8200 56 41 3 4 9 11 8200 56 41 3 2 4 11 
3.  109281 Dinesha 8300 56 32 12 3 6 11.1 8200 61 33 6 2 5 10.9 
4.  109182 Balamurugan 7000 66 30 4 5 10 10.7 7100 65 30 5 4 8 11.3 
5.  109912 Yogasiva varshini 8800 65 28 7 13 25 10.4 8700 63 32 5 6 12 11 
6.  111668/24 Safiya 8200 56 36 8 9 18 10 8200 57 37 6 5 10 10.7 
7.  111761/342 Selvaharish 8400 53 38 9 14 27 10.8 8300 54 40 6 7 14 10.5 
8.  2705 Harini 8200 50 39 11 12 24 10.4 8100 52 40 8 7 14 11 
9.  2935 Dinesh Kumar 8400 57 33 10 2 4 11.2 8400 56 35 9 2 4 11.5 
10.  6269 Murugan 7300 61 30 9 6 12 11 7400 59 34 7 4 8 10.6 
 
 
11.  7136 Grishma 9300 56 36 8 12 25 11.9 9200 58 36 6 8 16 11.3 
12.  6488 Muhammed Riyashkhan 8000 52 42 6 11 22 10.2 8000 56 41 3 7 14 10.5 
13.  8359 Sudha 9800 50 48 2 6 12 12.1 9700 52 46 2 4 8 12.3 
14.  8843 Muthayaa 8600 50 40 10 9 18 11.2 8500 51 42 7 5 10 11.6 
15.  8878 Arumugakani 8500 51 45 4 4 7 10.2 8500 52 45 5 4 8 10.6 
16.  10420 Samera 8100 57 37 6 10 20 9.8 8000 57 38 5 8 16 10 
17.  18063 Meharaj 9800 78 20 2 7 15 8.5 9800 61 35    4 4 7 8.3 
18.  30482 Muhammed Anifa 8100 56 31 13 4 9 11 8000 57 34    9 3 6 10.6 
19.  34451 Arifa  8300 51 34 15 5 10 10.8 8200 56 34 10 4 8 10.8 
20.  34757 Agirajahin 7800 56 44 2 3 7 11 7700 56 42 4 2 4 11.2 
 
 
Case Report of 20 out patients with Lasunathabitham 
S
.NO. 
OP NO. PATIENT NAME AGE / SEX 
No. of 
days 
treated 
Remarks 
01.  109304 Divya 10 FC 8 DAYS Moderate 
02.  109258 Muhaswaran 11 MC 9 DAYS Good 
03.  109281 Dinesha 8 MC 9 DAYS Good 
04.  109182 Balamurugan 8 MC 8 DAYS Moderate 
05.  109912 Yogasivavarshini 12 FC 8 DAYS Good 
06.  111668/24 Safiya 7 FC 8 DAYS Mild 
07.  111761/342 Selvaharish 11 MC 10 DAYS Good 
08.  2705 Harini 12FC 9 DAYS Good 
09.  2935 Dinesh Kumar 9 MC 8 DAYS Good 
10.  6269 Murugan 8 MC 11 DAYS Good 
11.  7136 Grishma 6FC 9 DAYS Moderate 
12.  6488 
Muhammed Riyas 
khan 
5 MC 10 DAYS Good 
13.  8359 Sudha 11FC 8 DAYS Good 
14.  8843 Muthayaa 11 MC 10 DAYS Good 
15.  8878 Arumugakani 11FC 8 DAYS Moderate 
16.  10420 Samera 6FC 9 DAYS Good 
17.  18063 Meharaj 12FC 8 DAYS Good 
18.  30482 Muhammed Anifa 5 MC 9 DAYS Mild 
19.  34451 Arifha 5FC 10 DAYS Good 
20.  34757 Agirajahin 5 MC 12 DAYS Good 
 
From this study, Out of 20 Patients 14 Patients (70%) had good Relief, 4 patients (20%) had 
moderate relief, 2 patients (10%) had mild relief.  
 
 
INVESTIGATIONS OF 20 OUT PATIENTS OF LASUNATHABITHAM 
S
SL. 
NO. 
OP. NO. Name of the Patient 
URINE ANALYSIS MOTION ANALYSIS 
Before Treatment After Treatment Before Treatment After Treatment 
Al
b Sug Dep Alb Sug Dep Ova Cyst Ova Cyst 
1.  109304 Divya Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
2.  109258 Muhaswaran Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
3.  109281 Dinesha Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
4.  109182 Balamurugan Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
5.  109912 Yogasivavarshini Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
6.  111668/24 Safiya Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
7.  111761/34
2 
Selvaharish Nil Nil  1-2 pus cells Nil Nil NAD Nil Nil Nil Nil 
8.  2705 Harini Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
9.  2935 Dinesh Kumar Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
10.  6269 Murugan Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
 
 
11.  7136 Grishma Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
12.  6488 Muhammed Riyas 
khan Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
13.  8359 Sudha Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
14.  8843 Muthayaa Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
15.  8878 Arumugakani Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
16.  10420 Samera Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
17.  18063 Meharaj Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
18.  30482 Muhammed 
Anifa Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
19.  34451 Arifha Nil Nil  1-2 pus cells Nil Nil NAD Nil Nil Nil Nil 
20.  34757 Agirajahin Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
 
  
 
 
DISCUSSION 
 Lasunathabitham is one of the Respiratory problem in paediatric age group, 
the clinical features of which are clearly described in various siddhar’s text. This 
disease most probably correlates with Tonsillitis in modern science.  
 In the study of 40 cases were treated at the post graduate department. 
Siddha methods of diagnosis were carried out and recorded in the selection 
proforma, and the diagnosis was confirmed with the help of modern investigations. 
The patients were treated with the drug Lasunathabitha Kudineer and clearly 
observed. The results and observations are discurred here under.  
1. Distribution according to age: 
 This study indicates the children’s under the age group of 5 to 10 years 
were commonly affected, Since they contributed to school going age group, 
overpopulation of the children had high extent of tonsillar infection.  
2. Distribution according to sex: 
 Among 40 cases of study 60% were female children and 40% were male 
children.  
3. Distribution according to socio economic status: 
 Most of the patients 75% belonged to low income group, 20% of the cases 
were middle income group and 5% of the cases were high income group. Due to 
poverty, overpopulation and unhygienic practices this disease is more prevalent 
among the poor. 
4. Distribution of paruva kaalangal: 
 According to paruva kaalangal the highest distribution (42.5%) was noticed 
in pinpani kaaalam, 40% patients are affected in Munpani kaalam, 17.5% of 
patients are affected in Elavenil kaalam.  
 
 
 
5. Diet history: 
 According to diet history 87.5% of cases had mixed diet, and 12.5% had 
vegetarian diet. The highest incidence of cases were observed in mixed diet of 
food habits.  
6. Family History: 
 According to family 88% of the cases had Negative family history, and 
12% of the case had positive family history. The higher incidence of cases had no 
relvant history.  
7. Distribution of Land: 
 Among the selected cases 97.5% of them were from Marutham land and 
2.5% of them were Neithal land. According to the siddha concept marutham land 
does not produce any disease. But due to altered life style and environmental 
conditions the incidence of this disease occurs in land of Marutham and Neithal.  
8. Distribution according to Uyir thathukkal: 
a) Derangement of Vatham: 
 Due to derangement of vatham, the following symptoms may occur. Pranan 
(100%) causes difficulty in breathing. Abanan (20%) causes constipation in some 
patients. Viyanan (30%) causes Fatigue, Uthanan (100%) causes cough & in some 
patients wheezing. Samanan (100%) causes difficult in controlling other vathams, 
Kirukaran was deranged in (25%) cause loss of appetite, cough, running nose, 
Devathathan (75%) cause tiredness in some cases.  
b) Derangements of Pitham: 
 Anilapitham was deranged in 62.5% of patients causing indigestion. 
Ranjakam was deranged in 75% of patients due to malnutrition and pallor, 
saathagam was deranged in 75% of patients causing limitations in their daily 
physical activities.  
 
 
c) Derangements of Kabam: 
 Due to derangements of Kabam, Avalambagam was deranged in 100% of 
patients causing difficulty in breathing. Kilethakam was deranged in 37.5% of 
patients causing poor apetite pothakam was deranged in 25% of patients causing 
variation in taste, Tharpagam 50% of cases affected.  
9. Distribution according to Ezhu Udal Kattugal: 
 In ezhu udal kattugal, saaram (100%) senner (87.5%), oon (100%) were 
affected causing General Fatigue, Anaemia, and swelling of the tonsils. 
10. En Vagai Thervugal: 
 According to this study, 40% of cases had pithakabam naadi, 30% of cases 
had kabapitha naadi 22.5% of cases had vathapitha naadi, 5% of cases had 
vadhakaba Naadi, Sparisam was affected in 37.5% of cases (Fever), Naa was 
affected in 30% of cases (coated and pallor) Niram was altered in 3.5% of cases 
due to anaemia. Mozhi was affected in 60% of cases due to hoarseness of voice, 
vizhi was affected in 37.5% of patients due to pallor. Malam, Mothiram was 
altered in 25% of cases due to constipation and oliguria. 
11. Nei Kuri: 
 In this study most of the patients had Kaba Neer (75%) which stood as a 
pearl indicating that the most predominant manifestation of the lasunathabitham is 
Kabam.  
12. Distribution according to aetiological facters: 
 Intake of cold food stuff cooldrinks, Ice cream, etc., seasonal variations 
contribute to 87.5% of the most common cause, 75% of cases were affected by 
living in congested areas, using same vessels by many 62.5% of cases were 
affected by drinking contaminated water, 25% of cases were affected by familial 
way.  
 
 
13. Distribution of clinical features: 
 Before treatment almost all cases (100%) were presented with sore throat 
and redness and swelling of the tonsil, it was reduced to 10%, 95% of cases had 
cough before treatment it reduced to 5%, 87.5% of cases had dysphagia and 
hoarseness of voice before treatment, it reduced to 5%, 75% of cases had cervical 
hymphadenitis, before treatment, it reduced to 7.5%, 50% of patients had Nasal 
congestion and Nasal discharge before treatment, it reduced to 2.5%, 37.5% of 
patients had fever before treatment it reduced to 0%, 25% of patients had distaste 
and constipation before treatment, it reduced to 1%, 12.5% of cases had Nausea, 
Halitosis before treatment, it reduced to 0%, 10% of cases had headache before 
treatment, it reduced to 0% Almost all the signs and symptoms were decreased 
after treatment. 
14. Lab Investigations: 
 Routine Examination of blood and urine and motion were done before and 
after treatment. In most of the cases (75%) etevated ESR and eosinophil count was 
decreased after treatment.  
15. Biochemical Analysis: 
 Qualitative analysis of the trial drug revealed the presence of ferrous iron 
which is more soluble and readily absorbable form that in treating children who 
are associated with anaemia. The study also indicates the presence of chloride, 
calcium, sulphate, starch, aminoacids etc., 
16. Antibacterial Activity: 
 Antibacterial activity of lasunathabitha kudineer showed that it inhibited the 
growth of bacterial strains of staphylococci and streptococci.  
 
 
 
 
17. Pharmacological Analysis: 
 Pharmacological Analysis showed the drug has significant anti – 
inflammatory, anti – histamine activity. 
18. RESULT: 
 Satisfactory improvement was reported in 3 days of commencement of 
treatment. Out of 40 cases 29 patients (72.5%) showed Good response with 
remarkable relief of symptoms, frequency of similar episodes is reduced. Moderate 
result was observed in 8 cases (20%) with decreased in sign and symptoms. In 3 
cases the result was mild (7.5%), as there was less significant improvement of 
symptoms. 
  
 
 
SUMMARY 
 The aim of this dissertation subject is to assess the efficacy of trial drug 
“Lasunathabitha Kudineer” for “Lasunathabitham” without any adverse 
effects. 
 Sufficient literatures with reference to Lasunathabitham was not found in 
siddha system. Hence from the available texts, signs, symptoms and 
characteristic features were collected and the medicine was chosen for the 
study.  
 The Etiopathogenesis and symptoms of Lasunathbitham have been 
correlated with that of Tonsillitis with evidence of literature.  
 Clinical diagnosis and selection of cases was based on clinical features 
described in Pillaipini Maruthuvam text book.  
 Laboratory diagnosis was done by modern methods of examination.  
 20 cases were selected and treated in IPD. Department of Kuzhanthai 
Maruthuvam, Govt siddha medical college, Palayamkottai for the clinical 
study.  
 The medicine choosen for treatment and management of Lasunathabitham 
was Lasunathabitha Kudineer (10 – 30ml) internally, twice a day. 
 The trial drug selection is based on its siddha pathological and 
pharmacological action to rectify the deranged Mukuttram and also due to 
its antiinflammatory, antihistamine effect of ingredients. 
   All the children were kept under strict dietary control during the treatment. 
The observation on effect of therapy was encouraging.  
 The documentation of observation made during the clinical study showed 
that the drug is clinically effective. 
 The Biochemical analysis of the trial drug had ferrous iron which adds to 
the clinical prognosis of Lasunathabitham by Lasunathabitha Kudineer.  
 Anti bacterial activity of Lasunathabitha Kudineer showed that it inhibited 
the growth of bacterial strain against streptococci and staphylococci. 
 
 
 In pharmacological analysis, the trial medicine Lasunathabitha kudineer had 
siginificant Anti – inflammatory, antihistamine action. Which help to 
improve the patients quality of life.  
With there benefits “Lasunathabitha Kudineer” can be deemed as an effective 
drug for “Lasunathabitham” (Tonsillitis). 
  
 
 
CONCLUSION 
 The Global burden of Tonsillitis in children increasing prevalence and its 
impact in reducing the quality of life in children has prompted the author to 
choose an effective drug without any side effects, it is believed to improve 
the quality of life in children.  
 The trial drugs are safe to the children.  
 The treatment of Lasunathabitham with Lasunathabitha Kudineer has 
showed Good response with no adverse effect and ensure to be safe, 
effective and simple to administration.  
 The trial drugs are in easy form of preparation.  
 The ingredients of trial drug are feasible and useful, these compounds may 
serves as potentially useful drug at lower cost.   
 Clinical results were found to be significant good improvement was found 
in 72.5% of cases, Moderate in 20% of cases and mild in 7.5% of cases.  
Therefore it is concluded that the trial drug “Lasunathabitha kudineer” 
along with the modalities of Pranayama proves to be excellent in attack the 
tonsillitis among children.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE II 
BIO -CHEMICAL ANALYSIS 
BIO -CHEMICAL ANALYSIS OF LASUNATHABITHA    
 KUDINEER PREPARATION OF THE EXTRACT 
             5gms of the drug was weighed accurately and placed in 250ml clean 
beaker Then 50ml of distilled water is added and dissolved well. Then it is boiled 
well for about 10 minutes. It is cooled and filtered in a 100ml volumetric flask and 
then it is makeup to 100ml with distilled water.  This fluid is taken for analysis. 
 
QUALITATIVE ANALYSIS  
S.NO 
 
             EXPERIMENT OBSERVATION  INFERENCE 
1 TEST FOR CALCIUM 
2ml of the above prepared extract 
is taken in a clean test tube. To 
this add 2ml of 4% Ammonium 
oxalate solution. 
A white precipitate 
is formed 
Indicates the 
presence  
of calcium 
2 TEST FOR SULPHATE: 
2ml of the extract is added to 5% 
barium chloride solution. 
A  white 
precipitate 
Is formed 
Indicates the 
presence  
of sulphate 
3 TEST FOR CHLORIDE: 
The extract is added with silver 
nitrate solution 
A white precipitate  
Is formed 
Indicates the 
presence  
 of chloride 
4 TEST FOR CARBONATE: 
The substance is treated with 
concentrated Hcl 
No brisk 
Effervessence is 
formed 
Absence of 
chloride 
5 TEST FOR STARCH: 
The extract is added with weak 
iodine solution. 
Blue colour is 
formed 
Indicates the 
presence 
of starch 
 
 
6 TEST FOR IRON FERRIC: 
The extract is acidified with 
Glacial acetic acid and potassium 
ferro cyanide. 
No blue colour is 
formed 
Abseence  of 
ferric iron 
7 TEST FOR IRON FERROUS: 
The extract is treated with 
concentrated Nitric acid and 
Ammonium thio cyanate solution. 
Blood red colour 
is formed 
Indicates the 
presence 
of ferrous iron 
8 TEST FOR PHOSPHATE: 
The extract is treated with 
Ammonium Molybdate and 
concentrated nitric acid. 
No yellow 
precipitate is 
formed 
 Absence of 
phosphate 
9 TEST FOR ALBUMIN: 
The extract is treated with 
Esbach’s Reagent. 
 No yellow 
precipitate is 
formed 
 Absence of 
Albumin 
10 TEST FOR TANNIC ACID: 
The extract is treated with ferric 
chloride. 
No colour change  Indicates the  
absence of 
Tannic acid 
11 TEST FOR 
UNSATURATION: 
Potassium permanganate solution 
is added to the extract. 
It gets 
decolourised 
Indicates the 
presence of 
unsaturated 
compound 
12 TEST FOR  THE REDUCING 
SUGAR 
5ml of Benedict’s qualitative 
solution is taken in a test tube and 
allowed to boil for 2 mts and 
added 8-10 drops of the extract 
and again boil it for 2 mts. 
No Colour 
Changes  
Indicates the 
Absence of 
reducing sugar 
 
 
 
 
 
 
 
13 TEST FOR AMINO ACID: 
One or two drops of the extract is 
placed on a filter paper and dried 
it well. After drying, 1% 
Ninnydrin is sprayed over the 
same and dried it well. 
Violet colour is 
formed 
 Indicates the 
presence of 
Amino acid 
14 TEST FOR ZINC: 
The extract is treated with 
potassium ferrocyanide. 
No white 
precipitate is 
formed 
Absence of 
Zinc 
 
The trial drug “LASUNATHABITHA KUDINEER” 
 Calcium 
 Suphate 
 Choride 
 Starch 
 Ferrous iron 
 Unsaturated compound 
 Amino acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EVALUATION OF  ANTI-INFLAMMATORY ACTIVITY OF 
LASUNATHABITHA KUDINEER 
The anti-inflammatory activities of Siddha formulation of Lasunathabitha 
kudineer at a dose of 15 ml/kg and 30 ml/kg were evaluated using carrageenan-
induced paw edema method. The inflammation was readily produced in the form 
of edema with the help of irritant such as carrageenan. Carrageenan is a sulphated 
polysaccharide obtained from sea weed (Rhodophyceae) and when injected cause 
the release of prostaglandins by the way it produces inflammation and edema. 
REQUIREMENTS: 
Animal                              : Albino rat (180-200 g) 
Drugs and chemicals          : Carrageenan (1%w/v), Diclofenac sodium (standard), 
Carboxy methyl cellulose   : (1%w/v), 
Digital plethysmo meter.    : U G O Basile (Italy) 
Test compounds                 : Lasunathabitha kudineer 
METHOD: 
Anti-inflammatory activity was performed by the following procedure of 
Bhandri et al(1) The animals were divided into 4 groups each having six animals. 
A freshly prepared suspension of carrageenan (1% w/v 0.1 ml) was injected to the 
planter region of left hind paw of each rat. One group was kept as control and the 
animals of the other groups were pretreated with the Lasunathabitha kudineer at 
two doses 15ml/kg and 30 ml/kg dissolved with 2 ml sterile water given through 
orally twice a day for 4 days after carrageenan treatment. The paw volumes of the 
test compounds, standard and control groups were measured at 24 hr, 48hr and 
72hr with the help of Digital plethysmometer (Ugo Basile, Italy). Mean increase in 
paw volume was measured and the percentage of inhibition was calculated. 
 
 
 
% Anti-inflammatory activity = (Vc-Vt / Vc) x 100 
Where, Vt-mean increase in paw volume in rats treated with test compounds, 
Vc-mean increase in paw volume in control group of rats. 
TABLE No.1 
ANTI-INFLAMMATORY ACTIVITY OF LASUNATHABITHA KUDINEER 
Treatment Dose (mg/kg) 
Paw volume(ml) as 
measured by mercury 
displacement at 72 
hour 
Percentage 
inhibition of paw 
edema 
Group I 
Normal saline 
10ml/kg orally 5.50±0.90 - 
Group II 
Standard 
10mg/kg I.P. 
Diclofenac sodium 
1.85±0.42 66.36%*a 
Group III 
Lasunathabitha 
kudineer 
15 ml/kg 2.18±0.50 60.36%*a 
Group IV 
Lasunathabitha 
kudineer 
30 ml/kg 1.95±0.40 64.54%*a 
 
 Data are expressed as Mean ± S.E.M. 
 Data were analyzed by one way ANOVA followed by Newman’s keul’s 
 multiple range tests, to determine the significance of the difference between 
 the control group and rats treated with the test compounds. 
 *a   Values were significantly different from normal control at P< 0.01 
Results 
Anti- inflammatory activity 
Both dose of Lasunathabitha kudineer at a doses of 15 ml/kg and 30ml/kg 
were tested for their Anti- inflammatory activity by using carrageenan Induced rat 
paw edema method and the results are tabulated in Table no 1.  The results reveals 
that both doses of Lasunathabitha kudineer  possesses significant Anti- 
inflammatory activity when compared to control group at p<0.01.  
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EVALUATION OF  ANTIHISTAMINIC AND ANTIANAPHYLACTIC 
ACTIVITY OF SIDDHA FORMULATION OF LASUNATHABITHA 
KUDINEER 
Introduction 
Allergy is one of the common diseases that affect mankind with diverse 
manifestations. The prevalence of allergy and asthma has risen in the recent years 
despite an improvement in the general health of the population.[1] Allergic 
diseases are responsible for significant morbidity and have severe economic 
impact.[2] Various epidemiological studies have identified the causes for an 
increase in the prevalence of upper and lower respiratory tract allergic diseases. 
Some of the postulated reasons are increasing environmental pollution [3] and 
increased predisposition of individuals producing excessive IgE through a major 
change in the gene pool, changing lifestyles, and an increasing awareness of the 
disorders.[4] Intensive research during the last several decades has highlighted the 
role of lymphocytes, immunoglobulins, mast cells, and various autacoids in the 
etiopathogenesis of allergic conditions. Inspite of the voluminous literature on the 
subject, the treatment of allergic diseases continues to be far from satisfactory. The 
available treatment options for upper and lower respiratory tract allergic diseases 
have major limitations owing to low efficacy, associated adverse events, and 
compliance issues.[5]  
AYUSH, an Indian system of medicine, has described several drugs from 
indigenous plant sources for use in the treatment of bronchial asthma and allergic 
disorders. In the present study, the effect of Siddha formulation of Lasunathabitha 
kudineer were studied on the active anaphylaxis and mast cell stabilization in rats, 
and histamine-induced bronchospasm in guinea pigs.  
 
Materials and Methods 
Animals 
Inbred Wistar rats (175–200 g) and guinea pigs (400–600g) of either sex 
housed in standard conditions (temperature22 ± 2° C, relative humidity 60 ± 5% 
and 12 h light/dark cycle) were used. They were fed with standard pellet diet and 
 
 
water ad libitum. The Institutional Animal Ethics Committee approved the 
experimental protocol. Histamine and horse serum were procured from Sigma 
Chemicals and toluidine blue from Loba-Chemie, Mumbai. Elisa kit for IgE was 
supplied by Orion diagnostics, Espoc, Finland. All other chemicals and reagents 
were procured from Hi-Media Laboratories limited, Mumbai. 
Mast cell stabilizing activity 
Treatment protocol 
Twenty-four rats were divided into Five groups of six animals in each group.  
Group I       served as control and received vehicle (water). 
Group II     (sensitized control group) 
GroupIII     served as the treatment control, which was treated with 
 Lasunathabitha kudineer   
 at a dose of 15 ml/kg body weight, in oral route. 
Group IV    served as the treatment control, which was treated with 
 Lasunathabitha kudineer       
                        at a dose of 30 ml/kg body weight, in oral route. 
 In group11 to group 1V were sensitized by injecting 0.5 ml of horse serum 
subcutaneously along with 0.5 ml of triple antigen containing 20,000 million 
Bordetella pertussis organisms (Serum Institute of India Ltd.,Pune), Once a day for 
14 days.  
On day 14, the rats were sacrificed 2 h after the treatment and the intestinal 
mesentry was taken out for the study on mast cells. Mesentries along with 
intestinal pieces were excised and kept in Ringer Locke solution (NaCl 154, KCl 
5.6, CaCl2 2.2, NaHCO3 6.0, glucose 5.55 mM/L of distilled water) at 37oC. The 
mesenteric pieces were challenged with 5% horse serum for 10 min after which the 
mast cells were stained with 1.0% toluidine blue and examined microscopically for 
the number of intact and degranulated mast cells.[6] 
 
 
 
 
Histamine-induced bronchospasm in guinea pigs 
Bronchospasm was induced in guinea pigs by exposing them to 1% 
histamine aerosol under constant pressure (1 kg/cm2) in an aerosol chamber (24 × 
14 × 24 cm) made of perplex 
Glass,of the three groups of six animals each. 
Group I served as control. 
GroupII     served as the treatment control, which was treated with 
Lasunathabitha kudineer   
 at a dose of 15 ml/kg body weight, in oral route. 
Group III    served as the treatment control, which was treated with 
Lasunathabitha kudineer       
                        at a dose of 30 ml/kg body weight, in oral route. 
         The animals were exposed to 1% histamine aerosol under constant pressure 
(1 kg/cm2) in an aerosol chamber on day 0 without any treatment. The end 
point,preconvulsive dyspnea (PCD) was determined from the time of aerosol 
exposure to the onset of dyspnea leading to the appearance of convulsions.[7] As 
soon as PCD commenced, the animals were removed from the chamber and 
exposed to fresh air. This PCD was taken as day 0 value. On days 1 and 5, 
2 h after the administration of the drug, the time for the onset of PCD was recorded 
as on day 0. 
Statistical analysis 
The results of various studies were expressed as mean ± SEM and analyzed 
statistically using one-way ANOVA, followed by Newmann keul’s multiple range 
tests. P<0.05 was considered statistically significant.The analysis was performed 
using Graphpad Prism software package (Version 4.0). 
RESULTS 
Mast cell stabilizing potential of Lasunathabitha kudineer  Antigen 
challenge resulted in significant degranulation of the mesentric mast cells. 
Pretreatment of sensitized animals with Lasunathabitha kudineer  at a dose of 
 
 
15ml and 30ml/kg, p.o., for 2 weeks resulted in a significant reduction in the 
number of disrupted mast cells (P <0.001) when challenged with horse serum.  
Effect on histamine-induced bronchospasm 
Lasunathabitha kudineer  at a dose of 15ml and 30ml/kg p.o., significantly 
prolonged the latent period of PCD (P <0.001) as compared to control, following 
exposure to histamine aerosols on day 5 [Table no. 2]. 
Discussion 
Experimental animal model of asthma is characterized by allergen-induced 
immediate airway constriction and late airway reactivity to a pharmacological 
vasoconstrictor such as histamine and leukotrienes. Histamine is a central mediator 
in the pathogenesis of allergic and inflammatory disorders. In the present study, 
Lasunathabitha kudineer  prolonged the latent period of PCD in guinea pigs 
following histamine aerosol. This may be suggestive of an antihistaminic activity 
following treatment with Lasunathabitha kudineer  . 
  Antigen challenge, in sensitized animals, results in the degranulation of 
mast cells, which is an important feature of anaphylaxis. In the present study, 
Lasunathabitha kudineer  showed marked protection against the mast cell 
degranulation following antigen challenge in sensitized animals. Mast cell 
stabilizing activity of Lasunathabitha kudineer  may be attributed to the presence 
of active constituents which are known for their mast cell stabilizing potential 
against antigen–antibody reaction and/or due to the suppression of IgE antibody 
production, which is responsible for degranulation mast cells.[8]  
This antianaphylactic and antihistaminic effect may be caused by the 
stabilization of the mast cell membrane, suppression of IgE, and inhibition of 
pathological effects induced by the release of inflammatory mediators in 
Lasunathabitha kudineer treated animals. All the above findings lend credence to 
the beneficial use of Lasunathabitha kudineer  in the treatment of asthma and 
related conditions. 
However, further studies with other experimental models, especially to explore the 
role of cytokines are warranted to substantiate the antiasthmatic and antiallergic 
activity of Lasunathabitha kudineer  . 
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TABLE NO:1 EFFECT OF Lasunathabitha kudineer,ON MAST CELL 
STABILIZATION IN SENSITIZED RATS 
 
 
 
 
 
 
 
 
 
 
 
 Values are expressed as Mean±S.E.M  *a significantly different from sensitized 
control at p<0.01 
 
TABLE NO 2 : Effect of Lasunathabitha kudineer on histamine induced 
bronchospasm in guinea pigs. 
 
GROUPS 
 PRE-CONVULSION DYSPNEA (PCD)(SEC) 
DAY 0 DAY 1 DAY 5 
GP 1 172.25±7.
30 
264±9.5 210.15±9.
5 
GP 2 
(Lasunathabitha 
kudineer 
15ml/kg) 
180.28±6.
55 
210±6.6 420±15.0*
a 
GP3 
(Lasunathabitha 
kudineer 
30ml/kg) 
178±6.40 220±8.2 412±14.0*
a 
 
 Values are expressed as Mean ±S.E.M *a Significantly different from control on 
day 5 at p<0.001 
 
 
 
 
 
GROUPS 
                     MAST CELLS 
INTACT DISRUPTED 
NORMAL CONTROL 82.30±3.85 16.35±0.90 
SENSITIZED RATS 11.95±0.80 86.75±2.60 
Lasunathabitha 
kudineer 15ml/kg 
63.15±2.42*a 34.55±1.35*a 
Lasunathabitha 
kudineer 30ml/kg 
62.30±2.25*a 35.30±1.20*a 
 
 
ANTIMICROBIAL  STUDIES 
AIM 
  To study the Anti-microbial action of   Lasunathabitha  Kudineer   
against Streptococcus, Staphylococcus. 
MEDIUM  
 Muller Hinton agar 
COMPONENTS OF MEDIUM  
 Beef extract   - 300gms/lit 
 Agar    - 17gms/lit 
 Starch   - 1.5gms/lit 
 Casein Hydroxylate - 17.5gms/lit 
 Distilled water  - 1000ml 
 PH    - 7.6 
PROCEDURE 
 The media was prepared from the components and poured and dried 
on a petri dish. The organism was streaked on the medium and the test drug  
(1gm drug in 10ml water) was placed on the medium. This is incubated at 
37C    for one over night and observed for night and observed for the 
susceptibility shown up clearance around the drug. 
RESULT: 
 The test drug Lasunathabitha  Kudineer  was Moderately sensitive 
against Streptococcus and  Staphylococcus. 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
                                              PALAYAMKOTTAI 
       PG. DEPT. OF KUZHANTHAI MARUTHUVAM 
    CONSENT FORM 
______________________________________________________ 
 An open clinical study to evaluate the safety and efficacy of Siddha sasthric 
formulation“LASUNATHABITHA KUDINEER”for the management 
“LASUNATHABITHAM”             
                                       CERTIFICATE BY INVESTIGATOR 
 I certify that I have disclosed all the details about the study in the terms 
readily understood by the parent. 
Date ……………….     Signature………….. 
place ……………….      Name ……………… 
CONSENT OF INFORMANT 
 I have been informed to my satisfaction, by the attending physician, the 
purpose of the clinical trial, and the nature of drug treatment and follow-up 
including the laboratory investigations to be performed to monitor and 
safeguard my Son / Daughter body functions. 
 I am aware of my right to opt out of the trial at any time during the 
course of the trial without having to give the reasons for doing so. 
 I am, exercising  my free power of choice; hereby give my consent to be 
included as a subject in the clinical trial of “LASUNATHABITHA 
KUDINEER”for the treatment of  “LASUNATHABITHAM” 
       Informant Signature:………. 
Date:       Informant  Name: …………. 
Place:       Patient Name:………………. 
Signature of Witness              Relationship:………………… 
     
  
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
POST–GRADUATE DEPARTMENT PALAYAMKOTTAI, 
TIRUNELVELI – 627 002. 
  Branch IV- KUZHANDHAI MARUTHUVAM. 
PROFORMA OF CASE SHEET FOR LASUNATHABITHAM 
 
Ward  :     Religion  : 
I.P.No :      Nationality  : 
Bed No :      Date of admission : 
Name  :     Date of discharge : 
Age  :     Diagnosis  : 
Sex  :     Result   : 
Father’s Name:     Medical Officer : 
Occupation : 
Income : 
Address :          
Informant : 
Complaints and Duration : 
History of Present illness : 
History of Previous illness  : 
Birth History   : 
 1) Antenatal history              
 2) Perinatal history 
 3) Neonatal history 
Developmental history : 
Dietic history  : 
Feeding history  : 
Family history  : 
Socio economic history : 
Immunization history : 
 
 
 
General conditions on examination: 
Consciousness  : 
Decubitus   : 
Stature   : 
  Height : 
  Weight : 
  Head Circumference: 
  Mid arm circumference: 
Nutrition   : 
Facies   : 
Skin changes  : 
Pallor   : 
Cyanosis   : 
Jaundice   : 
Brythema   : 
Haemangioma  : 
Lymphadenopathy : 
Clubbing   : 
Koilonychia  : 
Jugular Vein pulsation : 
Abdominal distention : 
Engorge veins  : 
Pedal Oedema  : 
Temperature  : 
Pulse     
Rate/Minute  : 
Rhythm  :  
Volume  : 
Character  : 
Peripheral pulses : 
Heart rate  : 
 
 
Rate/Minute  :  
Respiratory Rate 
 Rate/Minute :  
 Type  :  
 Character : 
Blood Pressure  :               
     Right   Left  
 Upper limb  : 
 Lower limb  : 
Congenital abnormalities (if any) 
SIDDHA ASPECTS 
 Nilam: 
 Kurinchi    : 
 Mullai     : 
 Marutham    : 
 Neithal    : 
 Palai     : 
Paruvakalam: 
 Kaar (Aavani – Purattasi)  : 
 Koothir (Iyppasi – Karthigai) : 
 Munpani (Markazhi – Thai) : 
 Pinpani (Masi – Panguni)  : 
 Elavenil (Chithirai – Vaikasi) : 
 Muthuvenil (Aani – Aadi)  : 
Udal Nilai 
 Vatham    : 
 Pitham    : 
 Kabam    : 
 Kalappu    : 
 
 
 
 
 Gunam: 
 Sathuvam    : 
 Rasatham    : 
 Thamasam    : 
 Mummalam 
 Malam    : 
 Moothiram    : 
 Viyarvai    : 
 Poripulangal 
 Mei     : 
 Vaai     : 
 Kan     : 
 Mooku    :      
 Sevi     : 
Kanmendhriyam: 
 Kai     :  
 Kaal     :  
 Vaai     :  
 Eruvaai    :  
 Karuvaai    :  
Pira Uruppukalin nilai: 
 Iruthayam    : 
 Puppusam    : 
 Eraippai    : 
 Kalleeral    : 
 Manneeral    : 
 Kudal     : 
 Siruneeragam   : 
 Siruneerpai    : 
 Moolai    : 
 
 
 
Uyir Thathukkal: 
 Vatham: 
  Pirannan   : 
  Abannan   : 
  Viyannan   : 
  Uthannan   : 
  Samannan   : 
  Naagan   : 
  Koorman   : 
  Kirukaran   : 
  Dhevathathan  : 
  Dhananjeyan   : 
Pitha: 
  Analam   : 
  Ranjegam   :   
  Sathagam   :  
  Pirasagam   :   
  Alosagam   : 
  
 
Kapha:       
  Avalambagam  : 
  Kilethagam   : 
  Pothagam   : 
  Tharpagam   : 
  Sandhigam   : 
Udal Thathukkal: 
 Saaram    : 
 Senneer    : 
 Oon     : 
 Kozhuppu    : 
 
 
 Enbu     :  
 Moolai    : 
 Sukkilam/Suronitham  : 
Ennvagai Thervugal: 
 Naa     : 
 Niram     : 
 Mozhi     : 
 Vizhi     : 
 Sparisam    :  
 
Malam   
 Niram     : 
 Edai     : 
 Erugal     : 
 Elagal     : 
Moothiram 
  Neerkuri    :    
  Niram    :  
  Edai    : 
  Manam   : 
  Nurai    :  
  Enjal    : 
Neikuri               : 
Naadi                : 
 
 
 
 
 
 
 
 
 
MODERN ASPECTS 
SYSTEMIC EXAMINATION: 
EXAMINATION OF RESPIRATORY SYSTEM: 
EXAMINATION OF UPPER RESPIRATORY TRACT: 
GENERAL EXAMINATION 
 Sore Throat  : 
 Fever   : 
 Dysphagia  : 
 Cough   : 
 Nasal Stuffiness : 
 Rhinitis  : 
 Headache  : 
 Dyspnea  : 
 Wheezing  : 
 Coryza  : 
LOCAL EXAMINATION 
NECK 
 Tonsillar node enlargement  : 
 Tenderness    : 
 Other cervical glands  : 
  Anterior   : 
  Posterior   : 
  Upper    : 
  Superficial   : 
  Deep    : 
EAR 
  Peri auricular node  : 
  Discharge   : 
NOSE  
  Rhinitis   : 
  Pus    : 
 
 
  Mucous   : 
  Ulceration   : 
  Polyp    : 
MOUTH 
Tonsils 
  Surface   : 
  Inflammation   : 
  Redness   : 
  Follicles   : 
  Ulceration   : 
  Haemorrhage   : 
  Mucous coating  : 
 Uvula 
  Inflammation   : 
  Elongation   : 
 Pharynx 
  Inflammation   : 
  Redness   : 
  Ulceration   : 
  Growth   : 
 Tongue 
  Coating   : 
  Ulceration   : 
  Growth   : 
 Teeth  
  Caries teeth   : 
 Gums 
  Gingivitis   : 
OTHERS: 
 Past history of Tonsillitis 
 Recurrence of attack 
 
 
 Familial history of Allergy 
 Associated Joint Pain 
 Associated haemorrhagic spots or follicles 
 Associated Nasal Allergy 
 Personal Habits 
Tendency for sweets, chocolates, cold stuffs 
Personal hygiene 
Living conditions 
 EXAMINATION OF CARDIOVASCULAR SYSTEM 
 EXAMINATION OF CENTRAL NERVOUS SYSTEM 
 EXAMINATION OF ABDOMEN 
 EXAMINATION OF URINARY SYSTEM 
Laboratory Investigations: 
Blood 
 Total WBC Count  : 
 Differential WBC Count : 
 E. S.R  ½ hr   :     
 1hr   : 
 Hemoglobin percentage : 
Urine: 
 Albumin   : 
 Sugar    : 
 Deposit   : 
Daily Progress 
 
 
 
Advice 
 
 
 
Date Symptoms Medicine 
   
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI 
BRANCH-IV KUZHANDHAI MARUTHUVAM 
   Admission – Discharge Sheet 
Name of the Medical Unit: 
I.P. NO  :       Occupation       : 
Bed no  :        Income                  : 
Ward   :        Nationality       : 
Name   :        Religion                  : 
Age   :        Date of Admission    : 
Sex   :        Date of discharge      : 
Permanent address:                                      Diagnosis      :  
Temporary address:                                      Results          : 
Informant  :       Medical officer           : 
 
S.No 
CLINICAL FEATURES(Signs and 
Symptoms) 
During 
Admission 
During 
Discharge 
1. Sore throat   
2. Cough    
3. Cough with expectoration   
4. Dysphagia   
5. Fever   
6 Headache   
7 Earache   
8. Anorexia   
9. Swollen & Erythema of the tonsils    
10. Cervical lymphadenitis   
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